Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal English
Coverage 168,303 Raw stories ingested 22,184 rewritten in CS_CZ • 3 to rewrite (last 2 days).
Agents 7 Live Pipeline agents
  • FMP Stock News Fetch every minute 19s ago
  • FMP Forex News Fetch every 5 min 3m ago
  • CoinGecko News Fetch every 5 min running now
  • FIO Stock News Fetch every 10 min 9m ago
  • Patria Stock News Fetch every 10 min 9m ago
  • Editorial rewrite Rewrite every minute 1m ago
  • Asset sync Assets every 1 hour 18m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

View
Details Date Content Source
2026-06-12 13:12 2mo ago
2026-06-03 08:30 3mo ago
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
MRVI Maravai Lifesciences Holdings
FMP Stock News
Original source text
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150 million term loan facility and a $30 million revolving credit facility. Borrowings under the new term loan facility, together with approximately $98.5 million of cash on hand, were used to prepay outs.
2026-06-12 13:12 2mo ago
2026-03-15 03:52 5mo ago
ArrowMark Colorado Holdings LLC Raises Stake in Sprout Social, Inc. $SPT
SPT Sprout Social
FMP Stock News
Original source text
ArrowMark Colorado Holdings LLC boosted its holdings in Sprout Social, Inc. (NASDAQ: SPT) by 9.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,723,921 shares of the company's stock after purchasing an additional 421,189 shares during the quarter. Sprout Social comprises 1.1%
2026-06-12 13:12 2mo ago
2026-03-18 09:00 5mo ago
Sprout Social Named #1 Social Listening Product in G2's 2026 Spring Reports, Achieving 59 Top Rankings Overall
SPT Sprout Social
FMP Stock News
Original source text
March 18, 2026 09:00 ET  | Source: Sprout Social, Inc

Sprout earned the #1 spot in 59 of G2’s 2026 Winter Reports, including the Grid® Report for Social Media Listening Tools, Social Customer Service and the Enterprise Grid® Report for Social Media Analytics.The company received 198 leader badges across all business segments and regions. CHICAGO, March 18, 2026 (GLOBE NEWSWIRE) -- Sprout Social (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced a sweep of honors in G2’s 2026 Winter Reports, earning 198 leader badges across all business segments—from small business to enterprise—and spanning every global region.

Sprout Social ranked #1 in 59 individual G2 reports, including the Grid® Report for Social Media Listening Tools, the Enterprise Grid® Report for Social Media Analytics and the Grid® Report for Social Customer Service. Driven by verified customer reviews, these rankings demonstrate the increasing strategic value and impact of Sprout’s platform for brands navigating the evolving social landscape.

Social media has become an immediate and rich source of market and customer insight. This recognition comes as Sprout Social advances social intelligence and AI innovations that help brands move from reactive listening to predictive decision-making. By turning social data into forward-looking intelligence through tools such as Sprout AI and its proprietary AI agent Trellis, Sprout enables organizations to anticipate change, strengthen customer trust and drive sustained growth.

“Social media is increasingly central to how organizations understand markets, customers and culture, and the industry is moving toward AI-driven approaches to make sense of that volume and complexity,” said Scott Morris, chief marketing officer at Sprout Social. “We are proud to be recognized by G2, which reflects both our consistency in the market and the growing role of social as a vital business tool. Social intelligence is helping organizations move from reactive engagement to predictive insight, using social data to better understand their customers, the market and what comes next.”

Sprout Social earned its place on these lists because of customer feedback, including:

“Sprout Social is among the best tools out there in this space: It's a mature, full-featured social media management platform that excels in analytics, governance, team workflows and cross-platform publishing. It truly offers a robust enterprise-grade experience.”

“Sprout Social offers AI-driven insights that act like a mini strategy consultant, providing valuable guidance for identifying customer pain points.”

“Sprout is an indispensable tool for any modern social media marketing team. Its content management, scheduling, and reporting capabilities are all excellent, and the influencer marketing platform stands out as the best in the industry.”

“Sprout Social has become an essential part of our marketing toolkit. The reporting features are especially strong—clear, customizable, and easy to share with stakeholders. We also rely heavily on the listening tools, which help us stay ahead of conversations and understand our audience more deeply.”

For more information about Sprout Social and its award-winning platform, visit www.sproutsocial.com.

About Sprout Social

Sprout Social is a global leader in social media management and analytics software, built on the belief that All Business is Social℠. Sprout’s intuitive platform puts powerful social data into the hands of tens of thousands of brands so they can deliver smarter, faster business impact. Named the #1 Best Software Product by G2’s 2024 Best Software Award, Sprout offers comprehensive publishing and engagement functionality, customer care, influencer marketing, advocacy, and AI-powered business intelligence. Sprout’s software operates across all major social media networks and digital platforms. For more information about Sprout Social (NASDAQ: SPT), visit sproutsocial.com.

Social Media Profiles:
www.x.com/SproutSocial
www.x.com/SproutSocialIR
www.facebook.com/SproutSocialInc
www.linkedin.com/company/sprout-social-inc-/
www.instagram.com/sproutsocial

Contact
Media:
Kaitlyn Gronek
Email: [email protected]
Phone: (773) 904-9674

Investors:
Lexi Johnson
Email: [email protected]
Phone: (312) 528-9166
2026-06-12 13:12 2mo ago
2026-03-19 10:36 5mo ago
After Plunging 22.0% in 4 Weeks, Here's Why the Trend Might Reverse for Sprout Social (SPT)
SPT Sprout Social
FMP Stock News
Original source text
Sprout Social (SPT - Free Report) has been on a downward spiral lately with significant selling pressure. After declining 22% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.

RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.

Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.

So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefiting from the inevitable rebound.

However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.

Here's Why SPT Could Experience a TurnaroundThe RSI reading of 29.9 for SPT is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.

This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering SPT in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 27.2% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.

Moreover, SPT currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
2026-06-12 13:12 2mo ago
2026-03-21 11:35 5mo ago
Sprout Social: Improving Fundamentals Pushing The Stock Into Deep Value Zone; Reiterating Buy
SPT Sprout Social
FMP Stock News
Original source text
Sprout Social remains a Buy despite a 50% stock decline, as fundamentals have improved and the valuation is now more attractive at 0.7x P/S. SPT consistently beats and raises revenue guidance, with strong customer metrics and AI-driven product innovation expected to drive future growth above current guidance. AI initiatives like Listening Agent, Insights Agent, and Trellis Studio are set to enhance monetization through usage-based pricing and differentiated platform capabilities.
2026-06-12 13:12 2mo ago
2026-03-25 14:04 5mo ago
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
SPT Sprout Social
FMP Stock News
Original source text
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo (SPT-300).
2026-06-12 13:12 2mo ago
2026-03-26 15:57 5mo ago
Buy Zillow, Sprout Social as AI Redefines Internet Services
SPT Sprout Social
FMP Stock News
Original source text
Macro factors currently driving the economy, such as inflation, interest rates, labor markets, supply chain issues and so forth have a varied impact on players in the extremely diverse Internet – Services industry, although a stronger economy is generally positive. Therefore, the ongoing war; declining consumer confidence mainly related to tariffs, inflation and jobs; and inflation-driven rising producer price index (PPI) may be considered negative for the Internet Services industry.

 Our picks are Zillow (Z - Free Report) and Sprout Social (SPT - Free Report) because of their growth prospects, AI adoption and cost cutting measures.

 Most industry players are heavily investing in artificial intelligence and machine learning as this allows them to provide additional features and differentiate their offerings. Being a capital-intensive industry with high fixed cost of operation and the fairly constant need to build infrastructure, a high interest rate isn’t very positive for it. Therefore, any rate cuts in 2026 would make us incrementally positive about the Internet Services industry.

 Valuation remains rich, but rising estimates indicate the existence of opportunities.

About the Industry Internet - Services companies are primarily those that rely on huge software and hardware infrastructure, referred to as their properties, to deliver various services to consumers. People can avail the services by accessing these properties with their personal connected devices from almost anywhere in the world.

Companies generally operate two models: an ad-based model and an ad-free model where the service is charged. Alphabet, Baidu and Akamai are some of the larger players while Crexendo, Upwork, Dropbox, Etsy, Shopify, Uber, Lyft and Trivago are some of the emerging players. Very large players (mainly Alphabet) tend to skew averages.

Because of the diversity of services offered, it is difficult to identify industrywide factors that could affect all players. The effect of macro factors such as inflation, rate hikes, supply chain issues and so forth vary.

Factors Determining Industry Performance Data is central to success in this industry, as it allows the players to build artificial intelligence (AI) models to improve the quality of services, create new technologies and services, and also to lower the cost of operation. AI is changing the way these companies operate: search is becoming conversational, content creation is becoming automated, AI agents are performing various tasks and personalized recommendations are now available at scale. Internet service providers are also able to differentiate their products based on the scale, flexibility and choice in AI-powered tools that they offer. The market is extremely competitive and smaller tools are getting commoditized. User interfaces across the web are being redesigned to adopt these changes. Larger companies often have the edge in AI because they have access to larger data sets that can be processed to further develop their AI.Monetization is increasingly shifting beyond traditional advertising as companies seek more stable and diversified revenue streams. While digital ads once dominated business models, growth in advertising has matured and become more cyclical, prompting platforms to expand into subscriptions, transaction fees, marketplaces and financial services. Companies now aim to capture value directly from user activity rather than only selling audience attention to advertisers. For example, platforms integrate payments, premium memberships, commerce tools, and enterprise software offerings to generate recurring or usage-based income. This transition improves revenue predictability, strengthens customer relationships, and reduces dependence on fluctuating ad markets.The internet services industry has undergone a major shift from prioritizing rapid user and revenue growth to emphasizing profitability and sustainable cash flow. During the low-interest-rate era, investors rewarded companies for expanding aggressively, even at the cost of large losses. However, higher interest rates and tighter capital markets have changed expectations, pushing companies to focus on operating efficiency, margin expansion and disciplined spending. Firms are now optimizing headcount, reducing customer acquisition costs and improving monetization of existing users rather than pursuing growth at any cost. This transition reflects a broader market preference for resilient business models capable of generating consistent earnings across economic cycles.Being a capital-intensive industry, there is the need to raise funds to build out costly infrastructure. Funds are also needed to maintain this infrastructure. Given the secular growth prospects, companies have continued infrastructure investments through 2023, 2024 and 2025 despite high interest rates. Most analysts expect interest rates to come down further in 2026, which would encourage further increase in capex. Ex-Alphabet PP&E displays some seasonality although the trend continues to swing upward, meaning that companies are investing heavily in their infrastructure.Regulation and antitrust pressure have become a defining force shaping the internet services industry as governments worldwide increase scrutiny of large digital platforms. Policymakers are focusing on issues such as market dominance, data privacy, algorithm transparency, app-store practices and digital advertising power. New regulations aim to limit anti-competitive behavior, protect consumer data and ensure fair access for smaller competitors, forcing companies to adjust business models, product design and expansion strategies. Compliance costs and legal risks are rising, while acquisitions and platform integrations face closer review. As a result, regulation is no longer a background risk but a core strategic factor influencing innovation, monetization and long-term growth decisions. Zacks Industry Rank Indicates Near-Term Pressure The Zacks Internet - Services industry is housed within the broader Zacks Computer and Technology sector. It carries a Zacks Industry Rank #176, which places it among the bottom 28% of 243 Zacks-classified industries.

The group’s Zacks Industry Rank, which is basically the average rank of all the member stocks, indicates that there are several opportunities in the space.

Looking at the aggregate earnings estimate revisions over the past year, improvements in both the 2026 and 2027 estimates have been more or less consistent, remaining relatively stronger in the last two months. As a result, the aggregate estimates for 2026 and 2027 are up a respective 12.1% and 13% over the past year.

Historically, the top 50% of Zacks-ranked industries outperforms the bottom 50% by a factor of more than 2 to 1. So the industry having moved into the bottom 50% indicates that investor sentiments remain muted.

Before we present a few stocks that you may want to consider for your portfolio, let’s take a look at the industry’s recent stock-market performance and valuation picture.

Industry Valuation: Rich Over the past year, the industry has returned more than both the broader Technology sector and the S&P 500. It had been trading below both indexes up until July but started pulling ahead thereafter. It has widened the gap with both since September last year.

The industry’s net gain of 65.6% over the past year is more than the broader sector’s 28.6% and the S&P 500’s 17.6%.

One-Year Price Performance

Image Source: Zacks Investment Research

Industry Appears Somewhat Overvalued On the basis of forward 12-month price-to-earnings (P/E) ratio, we see that the industry is currently trading at a 23.90X multiple, which is more or less its median value of 23.89X over the past year. This is a 15.3% premium to the S&P 500’s 20.72X and a 5.3% premium to the sector’s 29.07X.

Over the past year, the industry has traded in the range of 17.22X to 29.74X, a much broader range than the S&P’s 20.63X to 23.8X. The sector has traded in the 22.7X to 29.9X range.

Forward 12 Month Price-to-Earnings (P/E) Ratio

Image Source: Zacks Investment Research

2 Solid Bets The Internet Services industry is not in a good place at the moment mainly because of an uncertain macro and persistently high interest rates. Since the industry is highly diverse, it is only to be expected that some players would be doing exceedingly well while others not so much. We currently have a Zacks #2 (Buy) rating on both Zillow and Sprout Social discussed below.

Zillow Group Inc. (Z - Free Report) : Zillow operates a digital real-estate marketplace that connects homebuyers, sellers, renters, real-estate agents, landlords, and mortgage providers across the US. Its platforms allow users to search property listings, view price estimates (Zestimates), schedule tours and contact agents. Z

illow generates revenue primarily through advertising and lead-generation services sold to real-estate professionals, rental marketplace fees and mortgage origination services. The company is evolving into an end-to-end “housing super-app,” integrating search, financing, touring, transaction support and rentals into a unified online ecosystem designed to streamline residential real-estate transactions from discovery through closing.

The shift away from a listings website to a platform marketplace reduces Zillow’s dependence on ad revenue and opens up the possibility of multiple fees per transaction, driving up revenue per home sold. The company is well positioned to capitalize on its enormous traffic, strong brand recognition and nationwide network to generate solid growth. Additionally, it is investing in AI-based home recommendations, automated valuations, smart agent matching and

conversational search, all of which should facilitate the transition. Its revenue model promises more stable margins and its asset-light model will allow it to capitalize on housing market upcycles with limited balance sheet impact.

The one major downside to the whole story is its dependence on the interest rate, which is expected to remain high relative to historical standards. This drives up mortgage rates and therefore, home prices, and dries up buying intent. The prospect of lower home sales naturally drives down earnings expectations and hits the share price.

The company beat earnings estimates by 3 cents. Both 2026 and 2027 estimaes are unchanged in the last 30 days although both are down compared with 60 days ago. Analysts are currently looking for 2026 revenue and earnings growth of 15.1% and 28.1%, respectively. For 2027, they’re expecting 13.4% revenue growth and 28.9% earnings growth.

The shares of this Zacks Rank #2 (Buy) stock are down 38.1% over the past year.

Price and Consensus: Z

Image Source: Zacks Investment Research

Sprout Social, Inc. (SPT - Free Report) : Sprout Social, Inc. is a cloud-based software company that provides businesses with tools to manage, analyze and optimize their social-media presence across platforms such as Instagram, LinkedIn, TikTok, Facebook and X. Its subscription platform integrates content publishing, message management, customer service, social listening, influencer marketing and performance analytics into a unified dashboard.

Companies use Sprout to schedule posts, respond to customers through a centralized inbox, monitor brand sentiment and generate data-driven marketing insights. The company increasingly embeds AI to automate workflows, interpret social data, and help organizations turn online conversations into measurable business intelligence and customer engagement strategies.

As social media evolves from a mere marketing channel to a platform supporting a range of functions, including customer care, brand monitoring, crisis management, sales discovery and reputation analytics, the demand for a SaaS platform that can handle all these aspects for brands is also on the rise. Sprout has been gradually increasing its large enterprise focus because the broader volumes and scale are make this an obvious choice to drive revenue and profitability.

Enterprises don’t generally hop from one vendor to another, which lowers churn, adds predictability to revenue streams and supports pricing power. There’s also the possibility of gradually expanding services within accounts. In general, software delivery costs grow at a slower pace than subscriptions. So once investments stabilize, there is significant operating leverage, which leads to solid margin expansion.

There is an ongoing debate about whether AI is really helpful for the company since it lowers barriers to entry and increases competition, including from large social media players’ inhouse developments, while also increasing cost of innovation as features are quickly commoditized. However, Sprout does have a competitive moat in the vast amounts of unstructured datasets across platforms that it already possesses, along with its normalization and analytics operations, which require the kind of infrastructure that cannot be built in a hurry. Historical datasets also improve AI accuracy.

Sprout processes massive social datasets and embeds AI into sentiment analysis, automated engagement and campaign optimization. Customer reviews and rankings continue placing Sprout as a leader in social listening and analytics tools.

Sprout topped estimates in the last quarter, with earnings beating by 25%. The 2026 estimate has not changed in the last 30 days while the 2027 estimate increased 5 cents (4.4%). At these levels, they represent a 7.8% increase in revenue and a 14.6% increase in earnings for 2026 and a 7% revenue increase and 27.1% earnings increase in the following year.

The shares of this Zacks Rank #2 (Buy) stock have lost 77.2% of their value over the past year.

Price and Consensus: SPT

Image Source: Zacks Investment Research
2026-06-12 13:12 2mo ago
2026-04-06 16:05 5mo ago
Sprout Social to Announce First Quarter 2026 Financial Results on May 7, 2026
SPT Sprout Social
FMP Stock News
Original source text
April 06, 2026 16:05 ET  | Source: Sprout Social, Inc

CHICAGO, April 06, 2026 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced that it will report its financial results for the first quarter ending March 31, 2026 after market close on Thursday, May 7, 2026.

The financial results and business highlights will be discussed on a conference call and webcast scheduled at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) on Thursday, May 7, 2026. Online registration for this event conference call can be found at https://events.q4inc.com/analyst/. The live webcast of the conference call can be accessed from Sprout Social’s investor relations website at http://investors.sproutsocial.com.

Following completion of the events, a webcast replay will also be available at http://investors.sproutsocial.com for 12 months.

About Sprout Social

Sprout Social is a global leader in social media management and analytics software. Sprout’s intuitive platform puts powerful social data into the hands of tens of thousands of brands so they can deliver smarter, faster business impact. Named the #1 Best Software Product by G2’s 2024 Best Software Award, Sprout offers comprehensive publishing and engagement functionality, customer care, influencer marketing, advocacy, and AI-powered business intelligence. Sprout’s software operates across all major social media networks and digital platforms. For more information about Sprout Social (NASDAQ: SPT), visit sproutsocial.com.

Availability of Information on Sprout Social’s Website and Social Media Profiles

Investors and others should note that Sprout Social routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Sprout Social Investors website. We also intend to use the social media profiles listed below as a means of disclosing information about us to our customers, investors and the public. While not all of the information that the Company posts to the Sprout Social Investors website or to social media profiles is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media, and others interested in Sprout Social to review the information that it shares at the Investors link located at the bottom of the page on www.sproutsocial.com and to regularly follow our social media profiles. Users may automatically receive email alerts and other information about Sprout Social when enrolling an email address by visiting "Email Alerts" in the "Shareholder Services" section of Sprout Social's Investor website at https://investors.sproutsocial.com/.

Social Media Profiles:
www.twitter.com/SproutSocial
www.twitter.com/SproutSocialIR
www.facebook.com/SproutSocialInc
www.linkedin.com/company/sprout-social-inc-/
www.instagram.com/sproutsocial

Contact

Media:
Kaitlyn Gronek
Email: [email protected]
Phone: (773) 904-9674

Investors:
Alex Kurtz
Twitter: @SproutSocialIR
Email: [email protected]
Phone: (312) 528-9166
2026-06-12 13:12 2mo ago
2026-04-15 04:27 4mo ago
Justyn Russell Howard Sells 40,000 Shares of Sprout Social (NASDAQ:SPT) Stock
SPT Sprout Social
FMP Stock News
Original source text
Posted by Defense World Staff on Apr 15th, 2026

Sprout Social, Inc. (NASDAQ:SPT – Get Free Report) insider Justyn Russell Howard sold 40,000 shares of Sprout Social stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $5.03, for a total value of $201,200.00. Following the sale, the insider owned 7,417 shares in the company, valued at $37,307.51. This represents a 84.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Justyn Russell Howard also recently made the following trade(s):

On Wednesday, March 11th, Justyn Russell Howard sold 40,000 shares of Sprout Social stock. The stock was sold at an average price of $5.96, for a total value of $238,400.00. On Tuesday, March 3rd, Justyn Russell Howard sold 23,855 shares of Sprout Social stock. The stock was sold at an average price of $6.76, for a total value of $161,259.80. Sprout Social Price Performance SPT stock opened at $5.24 on Wednesday. The company has a quick ratio of 0.93, a current ratio of 0.93 and a debt-to-equity ratio of 0.20. Sprout Social, Inc. has a 52-week low of $4.92 and a 52-week high of $25.48. The stock’s 50 day moving average is $6.33 and its two-hundred day moving average is $9.09. The company has a market capitalization of $312.09 million, a PE ratio of -7.08 and a beta of 1.00.

Sprout Social (NASDAQ:SPT – Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.04. Sprout Social had a negative return on equity of 16.10% and a negative net margin of 9.47%.The company had revenue of $120.89 million for the quarter, compared to the consensus estimate of $118.68 million. Sprout Social has set its FY 2026 guidance at 0.880-0.970 EPS and its Q1 2026 guidance at 0.150-0.160 EPS. Analysts predict that Sprout Social, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Inflows and Outflows A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Diversified Trust Co boosted its position in Sprout Social by 6.1% during the 3rd quarter. Diversified Trust Co now owns 17,982 shares of the company’s stock valued at $232,000 after purchasing an additional 1,040 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Sprout Social by 2.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,127 shares of the company’s stock valued at $1,168,000 after purchasing an additional 1,265 shares during the period. Russell Investments Group Ltd. boosted its position in Sprout Social by 39.1% during the 4th quarter. Russell Investments Group Ltd. now owns 6,235 shares of the company’s stock valued at $70,000 after purchasing an additional 1,752 shares during the period. Tower Research Capital LLC TRC boosted its position in Sprout Social by 55.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,496 shares of the company’s stock valued at $115,000 after purchasing an additional 1,962 shares during the period. Finally, Summit Securities Group LLC boosted its position in Sprout Social by 399.0% during the 4th quarter. Summit Securities Group LLC now owns 2,520 shares of the company’s stock valued at $28,000 after purchasing an additional 2,015 shares during the period.

Analysts Set New Price Targets A number of equities research analysts have recently weighed in on SPT shares. Jefferies Financial Group lowered their price target on Sprout Social from $15.00 to $12.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Barclays lowered their price target on Sprout Social from $26.00 to $13.00 and set an “overweight” rating for the company in a report on Monday, January 12th. Needham & Company LLC lowered their price objective on shares of Sprout Social from $32.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, February 27th. KeyCorp lowered their price objective on shares of Sprout Social from $9.00 to $6.00 and set an “underweight” rating for the company in a research report on Friday, February 27th. Finally, Wall Street Zen raised shares of Sprout Social from a “hold” rating to a “buy” rating in a research report on Sunday, March 8th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $13.67.

Get Our Latest Research Report on Sprout Social

Sprout Social Company Profile (Get Free Report)

Sprout Social (NASDAQ: SPT) is a Chicago-based software company specializing in social media management solutions for businesses of all sizes. The company provides a cloud-based platform designed to help organizations improve their social media presence through a suite of tools for content scheduling, community engagement, social listening and analytics. Sprout Social’s platform is built to streamline the workflows of marketing, customer care and public relations teams by providing a centralized hub for managing multiple social channels.

The company’s product offerings include publishing and scheduling capabilities that allow users to plan and automate social content across networks such as Facebook, Instagram, Twitter, LinkedIn and Pinterest.

Recommended Stories Five stocks we like better than Sprout Social

Receive News & Ratings for Sprout Social Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sprout Social and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBryan Ball Sells 50,000 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock

NEXT HEADLINE »Adam Laponis Sells 2,597 Shares of Twist Bioscience (NASDAQ:TWST) Stock
2026-06-12 13:12 2mo ago
2026-04-29 09:00 4mo ago
New Sprout Social Research Reveals “Intelligence Gap” as Many Enterprises Fail to Act on Real-Time Consumer Insights
SPT Sprout Social
FMP Stock News
Original source text
April 29, 2026 09:00 ET  | Source: Sprout Social, Inc

Global study finds 86% of organizations missed opportunities due to delayed or siloed insights, while only 10% can act on real-time data within hours71% of business leaders predict social data will overtake traditional research in terms of strategic influence by 2029 CHICAGO, April 29, 2026 (GLOBE NEWSWIRE) -- Despite unprecedented access to real-time consumer data, most enterprises are still making decisions at yesterday’s speed. Social intelligence is the key to closing that gap, enabling organizations to capture signals, interpret meaning and act on insights in the moment, grounded in real-time data and market context. New research from Sprout Social finds that while 93% of professionals view social intelligence as critical to future growth, only 10% of organizations can translate those insights into meaningful business action within hours—creating a widening “intelligence gap.”

Based on a survey of 700 social and marketing professionals across the U.S., U.K. and Australia, The Intelligence Gap: Why Organizations Are Falling Behind in the Age of Real-Time Insight highlights a growing disconnect between the speed at which insights are generated and the pace at which businesses can act on them.

“With nearly six billion users, social media provides businesses with the most immediate, unfiltered view of their customers and the market ever available,” said Scott Morris, CMO of Sprout Social. “Advancements in AI are transforming social from a marketing channel into a source of enterprise-wide intelligence. This shift represents one of the most significant changes for marketers in decades, positioning them at the center of business decision-making. But capturing that value requires fundamental change. Organizations cannot power an AI-driven enterprise with legacy workflows built for a slower, linear era.”

This shift in importance is already recognized by the market: 74% of organizations say social intelligence delivers insights faster than traditional research, and two-thirds of professionals believe it will surpass traditional methods in strategic importance within three years. Yet, despite this belief, the report shows that only 10% of organizations can currently act on social data within hours. The inability to move at the speed of the consumer is proved costly, with 86% of professionals admitting they’ve missed potential business opportunities due to delayed, siloed, or underutilized insights.

The report identifies that this disconnect isn’t driven by a lack of data, but by how organizations are structured. Social intelligence remains largely confined to marketing, with only 36% of organizations saying it informs decisions in areas like product development or customer experience. At the same time, a disconnect between leadership and frontline teams suggests many organizations overestimate their maturity, creating a false sense of security that masks significant gaps in their ability to act.

Closing this gap is emerging as the next frontier of AI success. Organizations today have access to vital social data, and their investments in AI are making it possible to finally utilize these insights with speed and impact. The report makes it clear that unlocking this opportunity requires smart investment and a shift away from legacy workflows toward more connected, agile ways of working. Those who make this transition will be best positioned to compete in an economy defined by real-time change and will help define the next era of what’s possible.

Download the full report to explore the data behind the intelligence gap and how leading organizations are closing it.

About Sprout Social
Sprout Social is a leading AI-powered social intelligence platform, built on the belief that All Business is Social℠. Powered by Trellis, Sprout’s proprietary AI agent, the platform transforms real-time social media signals into actionable insights that drive business forward. Consistently recognized as a top software by G2, Sprout enables brands to deliver smarter, faster business impact through a suite of solutions including comprehensive publishing and engagement, customer care, influencer marketing, advocacy and predictive media intelligence. Sprout’s software operates across all major social networks and digital platforms. For more information about Sprout Social (NASDAQ: SPT), visit sproutsocial.com.

Social Media Profiles
www.x.com/SproutSocial 
www.x.com/SproutSocialIR 
www.facebook.com/SproutSocialInc 
www.linkedin.com/company/sprout-social-inc-/ 
www.instagram.com/sproutsocial 

Media Contact
Kaitlyn Gronek
Email: [email protected] 
Phone: (773) 904-9674
2026-06-12 13:12 2mo ago
2026-05-07 16:05 4mo ago
Sprout Social Announces First Quarter 2026 Financial Results
SPT Sprout Social
FMP Stock News
Original source text
Approximated TTM Subscription Revenue Contribution for ≥$30K ARR Customers Grew 21% year-over-year
Announced Share Repurchase Program with Initial Authorization of $50 Million

CHICAGO, May 07, 2026 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its first quarter ended March 31, 2026.

“We are pleased with our financial performance this quarter, highlighted by $24.7 million in non-GAAP free cash flow, strong non-GAAP profitability, and continued strength in our $30,000+ ARR customer cohort,” said Ryan Barretto, CEO of Sprout Social. “We are also excited to announce the company’s first ever share repurchase program with an initial authorization of $50 million, which highlights our disciplined approach to capital allocation.”

First Quarter 2026 Financial Highlights

Revenue

Revenue was $121.5 million, up 11% compared to the first quarter of 2025.Total remaining performance obligations (RPO) of $395.3 million as of March 31, 2026, up 10% year-over-year.Current remaining performance obligations (cRPO) of $281.7 million as of March 31, 2026, up 10% year-over-year. Operating Income (Loss)

GAAP operating loss was ($5.8) million, compared to ($11.2) million in the first quarter of 2025.Non-GAAP operating income was $14.1 million, compared to $12.5 million in the first quarter of 2025. Net Income (Loss)

GAAP net loss was ($6.3) million, compared to ($11.2) million in the first quarter of 2025.Non-GAAP net income was $13.6 million, compared to $12.5 million in the first quarter of 2025.GAAP net loss per share was ($0.11) based on 59.7 million weighted-average shares of common stock outstanding, compared to ($0.19) based on 57.9 million weighted-average shares of common stock outstanding in the first quarter of 2025.Non-GAAP net income per share was $0.23 based on 59.7 million weighted-average shares of common stock outstanding, compared to $0.22 based on 57.9 million weighted-average shares of common stock outstanding in the first quarter of 2025. Cash

Cash and cash equivalents totaled $111.6 million as of March 31, 2026, compared to $95.3 million as of December 31, 2025.Net cash provided by operating activities was $25.2 million, compared to $18.1 million in the first quarter of 2025.Non-GAAP free cash flow was $24.7 million, compared to $19.5 million in the first quarter of 2025. See “Use of Non-GAAP Financial Measures” below for definitions of Non-GAAP operating income (loss), Non-GAAP net income (loss), Non-GAAP net income (loss) per share and Non-GAAP free cash flow and the financial tables that accompany this release for reconciliations of our non-GAAP measures to their closest comparable GAAP measures. See “Key Business Metrics” below for how Sprout Social defines RPO, cRPO, the number of customers contributing $30,000 or more in ARR, the number of customers contributing $50,000 or more in ARR and approximated TTM subscription revenue contribution from customers contributing $30,000 or more in ARR.

Customer Metrics

Grew number of customers contributing $30,000 or more in ARR to 3,875 customers as of March 31, 2026, up 12% compared to March 31, 2025.Grew number of customers contributing $50,000 or more in ARR to 2,085 customers as of March 31, 2026, up 18% compared to March 31, 2025. Beginning in the fourth quarter of 2025, we replaced our disclosure of customers with ARR of $10,000 or more with customers with ARR of $30,000 or more. We believe this metric better reflects our strategic focus on larger customers and aligns with how management evaluates performance and allocates resources. Prior-period amounts have been presented for comparability.

 Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Number of customers contributing $30,000 or more in ARR3,1313,2263,3743,4513,5383,7113,8033,875Approximated TTM Subscription Revenue Contribution for ≥$30K ARR Customers (in millions)$191.1$206.2$219.2$231.8$243.3$255.2$268.0$280.1Approximated TTM Subscription Revenue Contribution for ≥$30K ARR Customers as a % of Total Subscription Revenue51.5%53.1%54.5%55.9%56.9%57.9%59.1%60.3%
Recent Customer Highlights

During the first quarter, we had the opportunity to grow with new and existing customers like Monster, Naterra International, CSL Behring, Reebok, and Roku. Recent Business Highlights

Sprout Social recently:

Released their 2026 Social Intelligence Report (link)Named the #1 social listening product in G2’s 2026 spring reports, achieving 59 top rankings (link)Hosted a platform overview and system of record and action webinar (link) Second Quarter and 2026 Financial Outlook

For the second quarter of 2026, the Company currently expects:

Total revenue between $121.7 million and $122.5 million.Non-GAAP operating income between $9.5 million and $10.3 million.Non-GAAP net income per share between $0.15 and $0.16 based on approximately 60.3 million weighted-average shares of common stock outstanding. For the full year 2026, the Company currently expects:

Total revenue between $492.5 million and $495.5 million.Non-GAAP operating income between $54.9 million and $60.4 million.Non-GAAP net income per share between $0.88 and $0.97 based on approximately 60.7 million weighted-average shares of common stock outstanding. The Company continues to expect a Non-GAAP operating margin of approximately 15% by the fourth quarter of fiscal 2026 and reiterates its 30% target for a Rule of 40 framework (as defined by year-over-year revenue growth plus current quarter non-GAAP operating margin) by the fourth quarter of fiscal 2027.

The Company’s second quarter and 2026 financial outlook is based on a number of assumptions that are subject to change and many of which are outside the Company’s control. If actual results vary from these assumptions, the Company’s expectations may change. There can be no assurance that the Company will achieve these results.

The Company does not provide guidance for operating loss, the most directly comparable GAAP measure to non-GAAP operating income, operating margin, the most directly comparable GAAP measure to non-GAAP operating margin, or net loss per share, the most directly comparable GAAP measure to non-GAAP net income per share, and similarly cannot provide a reconciliation between its forecasted non-GAAP operating income, non-GAAP operating margin and non-GAAP net income per share and these comparable GAAP measures without unreasonable effort due to the unavailability of reliable estimates for certain items. These items are not within the Company’s control and may vary greatly between periods and could significantly impact future financial results.

Share Repurchase Program

Today, the Company also announced that its board of directors (the “Board”) authorized a share repurchase program under which the Company may repurchase up to $50 million of its Class A common stock. The repurchase program authorizes the Company to repurchase its Class A common stock from time to time in the open market, in privately negotiated transactions, through block purchases, through Rule 10b5-1 trading plans, or by any combination of such methods, all in accordance with applicable securities laws and regulations. The timing and amount of any repurchase will be determined by the Company's management at its discretion. The repurchase program does not obligate the Company to repurchase any particular amount of Class A common stock, has no set termination date and may be modified, suspended or discontinued at any time at the Board’s discretion.

Conference Call Information

The financial results and business highlights will be discussed on a conference call and webcast scheduled at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) today, May 7, 2026. Online registration for this event conference call can be found at https://events.q4inc.com/analyst/. The live webcast of the conference call can be accessed from Sprout Social’s investor relations website at http://investors.sproutsocial.com.

Following completion of the events, a webcast replay will also be available at http://investors.sproutsocial.com for 12 months.

About Sprout Social

Sprout Social is a global leader in social media management and analytics software. Sprout’s intuitive platform puts powerful social data into the hands of tens of thousands of brands so they can deliver smarter, faster business impact. Named the #1 Best Software Product by G2’s 2024 Best Software Award, Sprout offers comprehensive publishing and engagement functionality, customer care, influencer marketing, advocacy, and AI-powered business intelligence. Sprout’s software operates across all major social media networks and digital platforms. For more information about Sprout Social (NASDAQ: SPT), visit sproutsocial.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “explore,” ”future,” “intend,” “long-term model,” “may,” “medium to longer term goals,” “might,” “outlook,” “plan,” “potential,” “predict,” “project,” “should,” “strategy,” “target,” “will,” “would,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. However, not all forward-looking statements contain these identifying words. These statements may relate to our market size and growth strategy, our estimated and projected costs, margins, revenue, expenditures and customer and financial growth rates, our Q2 2026 and full year 2026 financial outlook, our plans and objectives for future operations, growth, initiatives or strategies, including our investments in research and development, and share repurchases, and other statements that are not historical fact. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the forward-looking statements. These assumptions, uncertainties and risks include that, among others: we may not be able to sustain our revenue and customer growth rate in the future, including due to risks associated with our strategic focus on enterprise customers; price increases have negatively impacted and price increases and packaging changes may in the future negatively impact demand for our products, customer acquisition and retention and reduce the total number of customers or customer additions; our business would be harmed by any significant interruptions, delays or outages in services from our platform, our API providers, or certain social media platforms, or if we are unable to renew agreements governing access to the data provided by such APIs on terms acceptable to us or at all; if we are unable to attract potential customers through unpaid channels, or other sources of demand, including expansion opportunities from existing customers and outbound sales efforts or convert prospective customers and expansion opportunities into paid subscriptions, our business and results of operations may be adversely affected; technological advances in AI may in the future disrupt the social media industry, which could significantly reduce the demand for our services or otherwise adversely impact our business or reputation if we are unable to keep pace and navigate this evolving environment; we may be unable to successfully enter new markets, manage our international expansion and comply with any applicable international laws and regulations; we may be unable to integrate acquired businesses or technologies successfully or achieve the expected benefits of such acquisitions and investments; unstable market, economic, and geopolitical conditions, such as recession risks, effects of inflation, tariffs and trade tensions, changes in government spending, labor shortages, supply chain issues, geopolitical instability and uncertainty, and fluctuation in interest rates, have and could continue to adversely impact our business and that of our existing and prospective customers, which may result in reduced demand for our products; we may not be able to generate sufficient cash to service our indebtedness; covenants in our credit agreement may restrict our operations, and if we do not effectively manage our business to comply with these covenants, our financial condition could be adversely impacted; any cybersecurity-related attack, significant data breach or disruption of the information technology systems or networks on which we rely could negatively affect our business; changing regulations relating to privacy, information security and data protection could increase our costs, affect or limit how we collect and use personal information and harm our brand; and risks related to ongoing legal proceedings. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 27, 2026 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, to be filed with the SEC, as well as any future reports that we file with the SEC. Moreover, you should interpret many of the risks identified in those reports as being heightened as a result of the current and ongoing instability in market, economic, and geopolitical conditions. Forward-looking statements speak only as of the date the statements are made and are based on information available to Sprout Social at the time those statements are made and/or management's good faith belief as of that time with respect to future events. Sprout Social assumes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, except as required by law.

Use of Non-GAAP Financial Measures

We have provided in this press release certain financial information that has not been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). Our management uses these non-GAAP financial measures internally in analyzing our financial results and believes that these non-GAAP financial measures are useful to investors as additional tools to evaluate ongoing operating results and trends and in comparing our financial results with other companies in our industry, many of which present similar non-GAAP financial measures. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable financial measures prepared in accordance with GAAP and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. A reconciliation of our historical non-GAAP financial measures to the most directly comparable GAAP measures has been provided in the financial statement tables included in this press release, and investors are encouraged to review these reconciliations.

Non-GAAP gross profit. We define non-GAAP gross profit as GAAP gross profit, excluding stock-based compensation expense, amortization expense associated with the acquired developed technology from our acquisitions of Tagger Media, Inc. (“Tagger”) and NewsWhip Group Holdings Limited (“NewsWhip”), and restructuring charges. We believe non-GAAP gross profit provides our management and investors consistency and comparability with our past financial performance and facilitates period-to-period comparisons of operations, as it eliminates the effect of stock-based compensation, amortization expense and restructuring charges, which are often unrelated to overall operating performance.

Non-GAAP operating income. We define non-GAAP operating income as GAAP loss from operations, excluding stock-based compensation expense, amortization expense associated with the acquired intangible assets from the Tagger and NewsWhip acquisitions, restructuring charges and changes in the fair value of contingent consideration. We believe non-GAAP operating income provides our management and investors consistency and comparability with our past financial performance and facilitates period-to-period comparisons of operations, as it eliminates the effect of stock-based compensation, amortization expense, restructuring charges and changes in the fair value of contingent consideration, which are often unrelated to overall operating performance.

Non-GAAP operating margin. We define non-GAAP operating margin as non-GAAP operating income (loss) as a percentage of revenue.

Non-GAAP net income. We define non-GAAP net income as GAAP net loss, excluding stock-based compensation expense, amortization expense associated with the acquired intangible assets from the Tagger and NewsWhip acquisitions, restructuring charges and changes in the fair value of contingent consideration. We believe non-GAAP net income provides our management and investors consistency and comparability with our past financial performance and facilitates period-to-period comparisons of operations, as this non-GAAP financial measure eliminates the effect of stock-based compensation, amortization expense, restructuring charges and changes in the fair value of contingent consideration, which are often unrelated to overall operating performance.

Non-GAAP net income per share. We define non-GAAP net income per share as GAAP net loss per share attributable to common shareholders, basic and diluted, excluding stock-based compensation expense, amortization expense associated with the acquired intangible assets from the Tagger and NewsWhip acquisitions, restructuring charges and changes in the fair value of contingent consideration. We believe non-GAAP net income per share provides our management and investors consistency and comparability with our past financial performance and facilitates period-to-period comparisons of operations, as this non-GAAP financial measure eliminates the effect of stock-based compensation, amortization expense, restructuring charges and changes in the fair value of contingent consideration, which are often unrelated to overall operating performance.

Non-GAAP free cash flow. We define non-GAAP free cash flow as net cash provided by operating activities, less expenditures for property and equipment, interest payments on our revolving credit facility and payments related to restructuring charges. Non-GAAP free cash flow does not reflect our future contractual obligations or represent the total increase or decrease in our cash balance for a given period. We believe non-GAAP free cash flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash provided by our core operations that, after expenditures for property and equipment, interest payments on our revolving credit facility and payments related to restructuring charges, is available for strategic initiatives.

Non-GAAP sales and marketing expenses, non-GAAP research and development expenses and non-GAAP general and administrative expenses. Non-GAAP sales and marketing expenses, non-GAAP research and development expenses and non-GAAP general and administrative expenses are defined as sales and marketing expenses, research and development expenses and general and administrative expenses, respectively, less stock-based compensation expense, amortization expense associated with the acquired intangible assets from the Tagger and NewsWhip acquisitions, restructuring charges and changes in the fair value of contingent consideration. We believe these non-GAAP measures provide our management and investors with insight into day-to-day operating expenses given that these measures eliminate the effect of stock-based compensation, amortization expense associated with the acquired intangible assets from the Tagger and NewsWhip acquisitions, restructuring charges and changes in the fair value of contingent consideration.

Key Business Metrics

Remaining performance obligations (“RPO”). RPO, or remaining performance obligations, represents contracted revenue that has not yet been recognized, and includes deferred revenue and amounts that will be invoiced and recognized in future periods.

Current remaining performance obligations (“cRPO”). cRPO, or current RPO, represents contracted revenue that has not yet been recognized, and includes deferred revenue and amounts that will be invoiced and recognized in the next 12 months.

30% target for a Rule of 40. We define this target as year-over-year revenue growth plus current quarter non-GAAP operating margin equal to 30%.

Number of customers contributing $30,000 or more in ARR. We define number of customers contributing $30,000 or more in ARR as those on a paid subscription plan that had $30,000 or more in ARR as of a period end. We view the number of customers that contribute $30,000 or more in ARR as a measure of our ability to scale with our customers and attract larger organizations. We believe this represents potential for future growth, including expanding within our current customer base.

Number of customers contributing $50,000 or more in ARR. We define number of customers contributing $50,000 or more in ARR as those on a paid subscription plan that had $50,000 or more in ARR as of a period end. We view the number of customers that contribute $50,000 or more in ARR as a measure of our ability to scale with large customers and attract sophisticated organizations. We believe this represents potential for future growth, including expanding within our current customer base.

Approximated TTM Subscription Revenue Contribution for ≥$30K ARR Customers. This metric depicts our approximation of the trailing twelve month subscription revenue contribution from customers contributing $30,000 or more in ARR. We calculate this metric by averaging the ARR of these customers as of the end of the applicable quarter and the immediately preceding quarter and dividing by four to derive a quarterly revenue contribution estimate for this customer cohort. This quarterly estimate is then summed over the preceding four quarters to approximate a trailing twelve month revenue contribution for this customer cohort, subject to minor adjustments for rounding.

We believe that customers contributing $30,000 or more in ARR represent those customers that can benefit the most from our platform given their more sophisticated needs for social media management software as compared to customers below this spending threshold. We believe this metric is useful in measuring our success in serving this particular customer cohort. This metric does not reflect the actual revenue contribution by these customers over the trailing twelve month period, and should not be viewed in isolation as a substitute for revenue or any of our other financial measures presented in accordance with GAAP. We use this metric to approximate revenue contribution over a specified period because the historical data and account mapping is not available to present the actual revenue generated by this cohort of customers over a historical period.

While we no longer believe that ARR and number of customers are key performance indicators of Sprout Social’s business, these metrics are necessary for an understanding of how we define number of customers contributing $30,000 or more in ARR and number of customers contributing $50,000 or more in ARR. For this purpose, we define ARR as the annualized revenue run-rate of subscription agreements from all customers as of the last date of the specified period and we define a customer as a unique account, multiple accounts containing a common non-personal email domain, or multiple accounts governed by a single agreement or entity.

We no longer believe that the number of customers contributing $10,000 or more in ARR is a key performance indicator of Sprout Social’s business due to our evolving customer mix and we will no longer publicly disclose that metric. We believe that customers contributing $30,000 or more in ARR and approximated TTM subscription revenue contribution from customers contributing $30,000 or more in ARR are stronger indicators of Sprout Social’s performance in its target customer segments.

Availability of Information on Sprout Social’s Website and Social Media Profiles

Investors and others should note that Sprout Social routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Sprout Social Investors website. We also intend to use the social media profiles listed below as a means of disclosing information about us to our customers, investors and the public. While not all of the information that the Company posts to the Sprout Social Investors website or to social media profiles is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media, and others interested in Sprout Social to review the information that it shares at the Investors link located at the bottom of the page on www.sproutsocial.com and to regularly follow our social media profiles. Users may automatically receive email alerts and other information about Sprout Social when enrolling an email address by visiting "Email Alerts" in the "Shareholder Services" section of Sprout Social's Investor website at https://investors.sproutsocial.com/.

Social Media Profiles:
www.twitter.com/SproutSocial
www.twitter.com/SproutSocialIR
www.facebook.com/SproutSocialInc
www.linkedin.com/company/sprout-social-inc-/
www.instagram.com/sproutsocial

Contact

Media:
Kaitlyn Gronek
Email: [email protected]
Phone: (773) 904-9674

Investors:
Alex Kurtz
Twitter: @SproutSocialIR
Email: [email protected]
Phone: (312) 528-9166

Sprout Social, Inc.Consolidated Statements of Operations (Unaudited)(in thousands, except share and per share data)     Three Months Ended March 31,  2026   2025 Revenue   Subscription$120,020  $108,680 Professional services and other 1,477   609 Total revenue 121,497   109,289 Cost of revenue(1)   Subscription 27,435   24,473 Professional services and other 556   365 Total cost of revenue 27,991   24,838 Gross profit 93,506   84,451 Operating expenses   Research and development(1) 26,947   23,229 Sales and marketing(1) 48,546   47,452 General and administrative(1) 23,859   24,972 Total operating expenses 99,352   95,653 Loss from operations (5,846)  (11,202)Interest expense (667)  (514)Interest income 751   895 Other expense, net (163)  (168)Loss before income taxes (5,925)  (10,989)Income tax expense 411   231 Net loss$(6,336) $(11,220)Net loss per share attributable to common shareholders, basic and diluted$(0.11) $(0.19)Weighted-average shares outstanding used to compute net loss per share, basic and diluted 59,735,864   57,890,898     (1) Includes stock-based compensation expense as follows:    Three Months Ended March 31,  2026   2025 Cost of revenue$574  $746 Research and development 5,925   6,206 Sales and marketing 5,010   5,936 General and administrative 6,638   6,907 Total stock-based compensation expense$18,147  $19,795  Sprout Social, Inc.Consolidated Balance Sheets (Unaudited)(in thousands, except share and per share data)       March 31, 2026 December 31, 2025Assets   Current assets   Cash and cash equivalents$111,620  $95,268 Accounts receivable, net of allowances of $2,204 and $2,719 at March 31, 2026 and December 31, 2025, respectively 69,415   100,996 Deferred Commissions 27,909   26,995 Prepaid expenses and other assets 16,971   13,945 Total current assets 225,915   237,204 Property and equipment, net 10,169   9,864 Deferred commissions, net of current portion 56,077   57,049 Operating lease, right-of-use asset 9,395   9,810 Goodwill 167,122   167,122 Intangible assets, net 37,325   39,733 Other assets, net 2,595   2,280 Total assets$508,598  $523,062 Liabilities and Stockholders' Equity   Current liabilities   Accounts payable$9,489  $10,115 Deferred revenue 194,335   205,639 Operating lease liability 2,741   2,664 Accrued wages and payroll related benefits 14,945   20,549 Accrued expenses and other 15,605   17,294 Total current liabilities 237,115   256,261 Revolving credit facility 32,500   40,000 Deferred revenue, net of current portion 1,065   752 Operating lease liability, net of current portion 11,314   12,055 Other non-current liabilities 11,414   10,572 Total liabilities 293,408   319,640     Stockholders' equity       Class A common stock, par value $0.0001 per share; 1,000,000,000 shares authorized; 57,261,096 and 54,253,382 shares issued and outstanding at March 31, 2026, respectively; 56,576,444 and 53,607,556 shares issued and outstanding at December 31, 2025, respectively 5   5         Class B common stock, par value $0.0001 per share; 25,000,000 shares authorized; 6,036,301 and 5,829,357 shares issued and outstanding at March 31, 2026, respectively; 6,156,301 and 5,949,357 shares issued and outstanding at December 31, 2025, respectively 1   1 Additional paid-in capital 657,261   638,894 Treasury stock, at cost (38,031)  (37,768)Accumulated other comprehensive income -   - Accumulated deficit (404,046)  (397,710)Total stockholders’ equity 215,190   203,422 Total liabilities and stockholders’ equity$508,598  $523,062  Sprout Social, Inc.Consolidated Statements of Cash Flows (Unaudited)(in thousands)     Three Months Ended March 31,  2026   2025 Cash flows from operating activities   Net loss$(6,336) $(11,220)Adjustments to reconcile net loss to net cash provided by operating activities   Depreciation and amortization of property, equipment and software 922   1,225 Amortization of line of credit issuance costs 59   52 Accretion of discount on marketable securities -   (7)Amortization of acquired intangible assets 2,408   1,293 Amortization of deferred commissions 7,020   5,283 Amortization of right-of-use operating lease asset 415   341 Stock-based compensation expense 18,147   19,795 Provision for accounts receivable allowances 278   1,129 Change in fair value of contingent consideration (493)  - Other (65)  - Changes in operating assets and liabilities, excluding impact from business acquisition   Accounts receivable 31,303   18,122 Prepaid expenses and other current assets (3,559)  (3,229)Deferred commissions (6,962)  (7,577)Accounts payable and accrued expenses (6,266)  (1,487)Deferred revenue (10,991)  (4,790)Lease liabilities (664)  (826)Net cash provided by operating activities 25,216   18,104 Cash flows from investing activities   Expenditures for property and equipment (1,099)  (1,357)Proceeds from maturity of marketable securities -   2,750 Net cash (used in) provided by investing activities (1,099)  1,393 Cash flows from financing activities   Repayments of line of credit (7,500)  (5,000)Employee taxes paid related to the net share settlement of stock-based awards (263)  - Net cash used in financing activities (7,763)  (5,000)Net increase in cash, cash equivalents, and restricted cash 16,354   14,497 Cash, cash equivalents, and restricted cash   Beginning of period 97,203   90,418 End of period$113,557  $104,915 
The following schedule reflects our non-GAAP financial measures and reconciles our non-GAAP financial measures to the related GAAP financial measures (in thousands, except per share data):

Reconciliation of Non-GAAP Financial Measures     Three Months Ended March 31,  2026   2025 Reconciliation of Non-GAAP gross profit   Gross profit$93,506  $84,451 Stock-based compensation expense 574   746 Amortization of acquired developed technology 1,125   705 Restructuring charges -   416 Non-GAAP gross profit$95,205  $86,318     Reconciliation of Non-GAAP operating income  Loss from operations$(5,846) $(11,202)Stock-based compensation expense 18,147   19,795 Amortization of acquired intangible assets 2,328   1,213 Restructuring charges -   2,731 Change in fair value of contingent consideration (493)  - Non-GAAP operating income$14,136  $12,537     Reconciliation of Non-GAAP net income   Net loss$(6,336) $(11,220)Stock-based compensation expense 18,147   19,795 Amortization of acquired intangible assets 2,328   1,213 Restructuring charges -   2,731 Change in fair value of contingent consideration (493)  - Non-GAAP net income$13,646  $12,519     Reconciliation of Non-GAAP net income per share  Net loss per share attributable to common shareholders, basic and diluted$(0.11) $(0.19)Stock-based compensation expense 0.31   0.34 Amortization of acquired intangible assets 0.04   0.02 Restructuring charges -   0.05 Change in fair value of contingent consideration (0.01)  - Non-GAAP net income per share$0.23  $0.22     Reconciliation of Non-GAAP free cash flow   Net cash provided by operating activities$25,216  $18,104 Expenditures for property and equipment (1,099)  (1,357)Interest paid on credit facility 629   484 Payments related to restructuring charges -   2,249 Non-GAAP free cash flow$24,746  $19,480 
2026-06-12 13:12 2mo ago
2026-05-07 20:12 4mo ago
Sprout Social (SPT) Q1 Earnings and Revenues Top Estimates
SPT Sprout Social
FMP Stock News
Original source text
Sprout Social (SPT - Free Report) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +43.75%. A quarter ago, it was expected that this developer of cloud software would post earnings of $0.16 per share when it actually produced earnings of $0.2, delivering a surprise of +25%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Sprout Social, which belongs to the Zacks Internet - Services industry, posted revenues of $121.5 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.88%. This compares to year-ago revenues of $109.29 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Sprout Social shares have lost about 43.5% since the beginning of the year versus the S&P 500's gain of 7.6%.

What's Next for Sprout Social?While Sprout Social has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Sprout Social was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.21 on $121.56 million in revenues for the coming quarter and $0.94 on $493.13 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Services is currently in the bottom 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the broader Zacks Computer and Technology sector, CI&T Inc. (CINT - Free Report) , has yet to report results for the quarter ended March 2026. The results are expected to be released on May 11.

This company is expected to post quarterly earnings of $0.09 per share in its upcoming report, which represents a year-over-year change of +80%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

CI&T Inc.'s revenues are expected to be $134.48 million, up 21.3% from the year-ago quarter.
2026-06-12 13:12 2mo ago
2026-05-08 22:06 4mo ago
Sprout Social Q1 Earnings Call Highlights
SPT Sprout Social
FMP Stock News
Original source text
2 hours ago

Roots Q1 Earnings Call HighlightsMarketBeat

Roots (TSE:ROOT) reported higher first-quarter sales for fiscal 2026 as growth in its direct-to-consumer business and partner channels helped offset pressure from temporary gross margin headwinds and higher project-related expenses. President and Chief Executive Officer Meghan Roach said the compan

TSE:ROOT

Read Roots Q1 Earnings Call Highlights

2 hours ago

Motorpoint Group H2 Earnings Call HighlightsMarketBeat

Motorpoint Group (LON:MOTR) reported record retail volumes and a sharp increase in profit for its 2026 financial year, with management saying data-led pricing, improved vehicle supply and operational efficiency helped the used-car retailer expand margins while growing sales. Chief Executive Officer

LON:MOTR

Read Motorpoint Group H2 Earnings Call Highlights

Sort By

Time Frame

Alert Type

Keywords

Page 1 of 322
2026-06-12 13:12 2mo ago
2026-05-09 05:11 4mo ago
Sprout Social, Inc. (SPT) Q1 2026 Earnings Call Transcript
SPT Sprout Social
FMP Stock News
Original source text
Sprout Social, Inc. (SPT) Q1 2026 Earnings Call Transcript
2026-06-12 13:12 2mo ago
2026-05-13 09:00 3mo ago
Sprout Social Unveils its AI-Powered Social Intelligence Platform and the Expansion of its Proprietary AI Agent, Trellis
SPT Sprout Social
FMP Stock News
Original source text
May 13, 2026 09:00 ET  | Source: Sprout Social, Inc

The next-generation platform is designed to bridge the gap between social data and business action, surfacing real-time market signals from social to inform product development, customer care, and more.Trellis will be integrated across the Sprout ecosystem to uncover insights and improve workflows across Publishing, Listening, the Smart Inbox, and Reporting.Trellis Studio introduces customizable AI workflows that can be tailored to users’ unique goals and operational needs.
CHICAGO, May 13, 2026 (GLOBE NEWSWIRE) -- Sprout Social (Nasdaq: SPT) today announced the unveiling of its AI-powered social intelligence platform, designed to help organizations operationalize real-time, unfiltered market conversations at scale. Central to this launch is the upcoming expansion of Trellis, Sprout’s proprietary agentic AI engine. Purpose-built for social, Trellis will be integrated across the Sprout ecosystem — Publishing, Listening, the Smart Inbox, and Reporting — to help transform fragmented social data into organization-wide action.

Available to all customers in July, Trellis will evolve beyond Listening to become a conversational intelligence layer for the platform. By synthesizing social data across networks and combining it with insights from across Sprout, Trellis is designed to help teams ask complex questions and surface relevant, actionable insights faster.

This rollout also debuts Trellis Studio, a dedicated environment where organizations will be able to build bespoke AI workflows. Trellis Studio is designed to help teams streamline recurring workflows, so that social intelligence can be tailored to their unique KPIs and operational needs.

“Social is the fastest reflection of what people are thinking and feeling, yet most organizations lack the infrastructure to act on that data in real time,” said Scott Morris, CMO of Sprout Social. “What changes with social intelligence is not just access to more data, but the ability to turn that signal into strategic action across the business. When organizations can do that, social moves from a downstream function to the heart of how a business anticipates change and drives growth. In today’s market, failing to act on these signals can create a direct constraint on performance.”

The shift toward social-led strategy is fueled by a growing reliance on real-time insights for high-stakes decision-making. Sprout’s latest research reveals that 71% of marketing directors expect social data to surpass traditional market research in shaping enterprise strategy by 2029. However, this evolution demands more than just access to information. It requires a fundamental organizational capability to bridge the gap between insight and execution at a moment's notice. With this launch, Sprout aims to close this gap, providing automation and agentic workflows built to turn signals into action faster across the business.

"AI is only as powerful as the data that informs it. Unlike general-purpose models, Trellis is uniquely valuable because of its access to real-time, native social data across multiple networks,” said Srinivas Somayajula, Chief Product Officer at Sprout Social. “When customer sentiment shifts or a competitive threat emerges, organizations cannot afford to miss the moment. Foundational models lack visibility into these signals in real time, but Trellis delivers, helping to transform network-native social data into decision-ready intelligence exactly when it matters most.”

Sprout’s AI-powered social intelligence platform focuses on four key pillars of value:

Predictive Media Intelligence: Leveraging agentic AI to help detect shifts in industry narratives as they emerge, allowing brands to respond proactively.Full-Funnel Social Optimization: Helping bridge the gap between social engagement and ROI through AI-powered insights designed to align social performance with broader business goals.Scalable Social Support: Moving beyond reactive replies to proactive engagement. AI helps surface the highest-priority interactions, enabling teams to provide personalized service at a global scale.Authentic Brand Amplification: Identifying high-affinity advocates and creators through AI-driven recommendations to extend brand reach with authenticity. These innovations, along with the findings of the 2026 Social Intelligence Report, will be showcased today during Breaking Ground, Sprout's quarterly showcase of the company's latest product updates and cutting-edge industry insights.

About Sprout Social

Sprout Social is a leading AI-powered social intelligence platform, built on the belief that All Business is Social℠. Powered by Trellis, Sprout’s proprietary AI agent, the platform is designed to transform real-time social media signals into actionable insights that drive business forward. Consistently recognized as a top software by G2, Sprout enables brands to deliver smarter, faster business impact through a suite of solutions including comprehensive publishing and engagement, customer care, influencer marketing, advocacy and predictive media intelligence. Sprout’s software operates across all major social networks and digital platforms. For more information about Sprout Social (NASDAQ: SPT), visit sproutsocial.com.

Social Media Profiles
www.x.com/SproutSocial
www.x.com/SproutSocialIR
www.facebook.com/SproutSocialInc
www.linkedin.com/company/sprout-social-inc-/
www.instagram.com/sproutsocial

Media Contact
Kaitlyn Gronek
Email: [email protected]
Phone: (773) 904-9674

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “can,” “continue,” “could,” “expect,” “explore,” ”future,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “strategy,” “target,” “will,” “would,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. However, not all forward-looking statements contain these identifying words. These statements may relate to the expected timing, availability and capabilities of our products and platform features, including Trellis and Trellis Studio; the anticipated benefits of our AI-powered social intelligence platform; statements about market trends, including the growing importance of social data in enterprise decision-making; our ability to develop and deliver AI-driven features and functionality; our market size and growth strategy, our plans and objectives for future operations, growth, initiatives or strategies, including our investments in research and development, and other statements that are not historical fact. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the forward-looking statements. These assumptions, uncertainties and risks include that, among others: the expected timing and availability of product features, including Trellis and Trellis Studio, may be delayed or may not be released as described; new products and features may not perform as intended or achieve the market acceptance we anticipate; our AI-powered features depend on access to social media data from third-party platforms, which may be restricted, limited or terminated; our business would be harmed by any significant interruptions, delays or outages in services from our platform, our API providers, or certain social media platforms, or if we are unable to renew agreements governing access to the data provided by such APIs on terms acceptable to us or at all; technological advances in AI may in the future disrupt the social media industry, which could significantly reduce the demand for our services or otherwise adversely impact our business or reputation if we are unable to keep pace and navigate this evolving environment; the AI and machine learning models underlying our platform features may produce inaccurate or unexpected results; unstable market, economic, and geopolitical conditions, such as recession risks, effects of inflation, any cybersecurity-related attack, significant data breach or disruption of the information technology systems or networks on which we rely could negatively affect our business; changing regulations relating to privacy, information security and data protection could increase our costs, affect or limit how we collect and use personal information and harm our brand; and rapidly evolving laws, regulations and industry standards relating to AI could affect or limit how we develop and deploy AI-powered features. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 27, 2026 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 8, 2026, as well as any future reports that we file with the SEC. Moreover, you should interpret many of the risks identified in those reports as being heightened as a result of the current and ongoing instability in market, economic, and geopolitical conditions. Forward-looking statements speak only as of the date the statements are made and are based on information available to Sprout Social at the time those statements are made and/or management's good faith belief as of that time with respect to future events. Sprout Social assumes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, except as required by law.
2026-06-12 13:12 2mo ago
2026-05-29 11:46 3mo ago
Sprout Social: Record Q1, AI Fears Are Overdone
SPT Sprout Social
FMP Stock News
Original source text
Sprout Social: Record Q1, AI Fears Are Overdone
2026-06-12 13:12 2mo ago
2026-06-11 12:18 2mo ago
Procore Technologies vs. Sprout Social: Which Technology Stock Is a Better Buy in 2026?
SPT Sprout Social
FMP Stock News
Original source text
Will digitizing the construction site or social media management provide better opportunities? Choosing between Procore Technologies (PCOR 3.08%) and Sprout Social (SPT +0.71%) requires understanding their distinct market niches.

Procore focuses on unifying the complex construction lifecycle through its cloud platform, while Sprout Social streamlines social media engagement and intelligence for brands. Both companies are navigating a shifting landscape where investors are increasingly prioritizing sustainable growth and profitability over raw expansion.

Procore provides a unified software platform that helps owners, contractors, and subcontractors manage everything from project design to completion. By centralizing data and communication, the company aims to reduce waste and improve safety among tech stocks serving industrial sectors. While specific major customers are not disclosed, the platform serves a diverse global market of nearly 18,000 organic customers.

In FY 2025, revenue reached nearly $1.3 billion, representing growth of approximately 14.8% compared to the prior year. Despite this growth, the company reported a net loss of roughly $100.8 million, though its net margin improved to negative 7.6% from negative 9.2% in FY 2024. This trend shows the business is narrowing its losses as it scales its operations.

As of its December 2025 balance sheet, the debt-to-equity ratio is approximately 0.1x. This ratio measures total debt against shareholder equity, with a lower number suggesting the company relies less on borrowed money. The current ratio, which measures a company's ability to pay short-term obligations with short-term assets, is close to 1.3x. Free cash flow for the period was nearly $215.1 million. Note that stock-based compensation represented roughly 79.8% of operating cash flow, which inflates reported cash generation since SBC is a non-cash expense added back in the cash flow statement.

Sprout Social offers an AI-powered platform that centralizes social media publishing, analytics, and customer engagement for businesses. Its software helps brands understand social data and manage their online presence across multiple networks like LinkedIn and TikTok. The company serves roughly 30,000 customers, though it does not disclose specific major individual clients in its filings.

For FY 2025, the company generated revenue of approximately $457.5 million, which is an increase of nearly 12.7% year-over-year. It reported a net loss of close to $43.3 million for the same period. While still unprofitable, its net margin improved to negative 9.5% compared to negative 15.3% in the previous fiscal year.

Based on the December 2025 balance sheet, the debt-to-equity ratio is roughly 0.3x. This metric compares total debt to the value of shareholder equity to help investors understand how the business is funded. Its current ratio is approximately 0.9x, indicating the company has slightly fewer short-term assets than short-term liabilities. Free cash flow for FY 2025 was nearly $46 million. Note that stock-based compensation represented roughly 181.3% of operating cash flow, meaning reported cash generation is heavily inflated by this non-cash add-back.

Risk profile comparisonProcore Technologies faces significant risks from the cyclical nature of the construction industry, which can be slowed by high interest rates or rising material costs. The company is also involved in litigation, including a 2024 trade secret misappropriation lawsuit from Oracle. Furthermore, new regulations like the EU AI Act could impose heavy fines if the company fails to comply with strict artificial intelligence standards. Reliance on Amazon for infrastructure also creates operational risk if service disruptions occur.

Sprout Social is highly dependent on access to third-party social media platforms, and losing access to data from companies like Meta Platforms or X could harm its service. It also faces legal risks, including a 2024 securities class action lawsuit filed against its executives. Like many software firms, it relies on Amazon for cloud infrastructure, meaning any service outages could prevent customers from using the platform. Regulatory compliance with international data laws remains a constant cost and liability risk.

Valuation comparisonSprout Social appears significantly cheaper than Procore Technologies when looking at its P/S ratio and Forward P/E, which compare price to revenue and future earnings estimates respectively.

MetricProcore TechnologiesSprout SocialSector BenchmarkForward P/E27.2x7.5x32.2xP/S ratio5.2x0.9xSector benchmark uses the SPDR XLK sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?I'd go with Procore. These two companies serve completely different markets, but as standalone investments in 2026, the comparison isn't particularly close.

Procore dominates a massive, underpenetrated market. Construction is one of the least digitized industries in the world, and Procore is the clear platform of choice for managing it. The company is growing steadily, raising its outlook, generating meaningful free cash flow, and leaning into AI in a way that could meaningfully expand what the platform does for customers. That's an enticing long-term setup.

Sprout Social is doing fine, with revenue growing, profitability improving, and the company moving upmarket toward larger enterprise customers. But the social media management space is crowded and competitive, and the stock has really underperformed. Growth has leveled out, and while management has a credible path toward better margins, the urgency of the opportunity feels more limited.

Procore is playing in a bigger, less competitive sandbox, and it's executing well. For a long-term investor, that's the more exciting place to be.
2026-06-12 13:12 2mo ago
2026-05-19 08:00 3mo ago
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
EXEL Exelixis
FMP Stock News
Original source text
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has entered into a clinical development collaboration with Merck, known as MSD outside of the United States and Canada, to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in combination with zanzalintinib in STELLAR-316, a planned phase 3 pivotal trial in patients with resected stage II/III colorectal cancer (CRC). Under the terms of th.
2026-06-12 13:12 2mo ago
2026-05-19 11:00 3mo ago
Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
EXEL Exelixis
FMP Stock News
Original source text
Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
2026-06-12 13:12 2mo ago
2026-05-20 15:35 3mo ago
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
EXEL Exelixis
FMP Stock News
Original source text
Key Takeaways Exelixis and Merck will study zanzalintinib plus Keytruda Qlex in phase III CRC trial STELLAR-316.EXEL plans to launch STELLAR-316 in mid-2026 for MRD-positive stage II/III colorectal cancer.Zanzalintinib NDA with Tecentriq in metastatic CRC faces FDA action date of Dec. 3, 2026. Exelixis (EXEL - Free Report) announced a clinical development collaboration with pharma giant Merck & Co. (MRK - Free Report) to evaluate its pipeline candidate, zanzalintinib, in combination with subcutaneous Keytruda Qlex in the planned phase III STELLAR-316 study for resected stage II/III colorectal cancer (CRC).

Under the agreement, Exelixis will sponsor the STELLAR-316 study, while Merck will provide Keytruda Qlex for use in the study.

Exelixis expects to initiate STELLAR-316 in mid-2026.

Year to date, Exelixis’ shares have risen 11.1% against the industry’s decline of  2.7%.

Image Source: Zacks Investment Research

More on EXEL’s Efforts to Advance ZanzalintinibZanzalintinib is a novel oral kinase inhibitor that inhibits the activity of the TAM kinases (TYRO3, AXL, MeR), MET and VEGF receptors.

The late-stage STELLAR-316 will evaluate zanzalintinib with and without Keytruda Qlex in patients with resected stage II/III CRC who, following definitive therapy, have tested positive for molecular residual disease (MRD+) and have no radiographic evidence of disease — a high-risk population with substantial unmet need.

Keytruda is approved for several types of cancer.

The collaboration with Merck adds external validation to the zanzalintinib program.

Earlier this year, Exelixis partnered with Natera (NTRA - Free Report) , a global leader in cell-free DNA and precision medicine, for this study.

Natera will supply its Signatera assay to identify eligible MRD-positive patients for enrollment, further integrating precision medicine into the program.

EXEL Seeks to Diversify Portfolio Beyond CabometyxZanzalintinib represents the company’s most significant near-term catalyst.

Exelixis’ new drug application seeking approval of zanzalintinib in combination with Roche’s (RHHBY - Free Report) Tecentriq for previously treated metastatic CRC is under review in the United States. The targeted population includes patients who have already received standard chemotherapy regimens, including fluoropyrimidine-, oxaliplatin- and irinotecan-based therapies, as well as anti-EGFR treatment for RAS wild-type disease.

The regulatory body set a target action date of Dec. 3, 2026.

A potential approval will broaden the company’s portfolio and reduce dependence on its lead drug, Cabometyx.

Roche’s Tecentriq is a cancer immunotherapy that is approved around the world, either alone or in combination with targeted therapies and/or chemotherapies, for various types of cancer.

Exelixis collaborated with MRK in October 2024 to advance zanzalintinib.

In April 2026, MRK initiated LITESPARK-034, a phase III study evaluating zanzalintinib plus Welireg (belzutifan) versus Welireg and placebo in previously treated advanced renal cell carcinoma (RCC) patients who progressed after PD-1/L1 and VEGFR-TKI therapies.

This marks the second Merck-sponsored phase III study under the collaboration, following LITESPARK-033 (launched in December 2025), which is assessing the combination against cabozantinib in first-line advanced RCC post-adjuvant immunotherapy.

Exelixis also announced two additional studies of zanzalintinib — STELLAR-202, a planned phase II trial evaluating the drug in combination with MRK’s blockbuster drug Keytruda (pembrolizumab) as maintenance therapy in squamous non-small cell lung cancer, and a new expansion cohort in the ongoing phase Ib/II STELLAR-002 study assessing zanzalintinib plus docetaxel in metastatic castration-resistant prostate cancer patients with measurable disease.

EXEL’s Zacks Rank
2026-06-12 13:12 2mo ago
2026-05-20 16:00 3mo ago
Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
EXEL Exelixis
FMP Stock News
Original source text
Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
2026-06-12 13:12 2mo ago
2026-05-21 17:00 3mo ago
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
EXEL Exelixis
FMP Stock News
Original source text
– Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented –

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX® (cabozantinib), and its investigational oral kinase inhibitor, zanzalintinib, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 29 – June 2 in Chicago.

“The presentations at ASCO this year highlight the continued progress of our strategy to build upon the well-established therapeutic profile of CABOMETYX and accelerate the development of zanzalintinib, our next oncology franchise molecule,” said Dana T. Aftab, Ph.D., Executive Vice President, Research and Development, Exelixis. “New analyses from the phase 3 CABINET pivotal trial that further reinforce the foundational role of CABOMETYX in patient care, and findings from the phase 3 STELLAR-303 pivotal trial evaluating our investigational therapy, zanzalintinib, in metastatic colorectal cancer, will be presented. These collective data sets are a testament to our team’s dedication to improving the standards of care for patients with cancer.”

Studies to be presented at the 2026 ASCO Annual Meeting include:

Abstract Title

Presentation

Session Title

Session Date/Time

Cabozantinib

A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801)

Oral Abstract #4500

Genitourinary Cancer – Kidney and Bladder

Friday, May 29
2:45 – 2:57 p.m. CDT

Interim analysis of CaboMain: A prospective, single-arm phase 2 clinical trial of cabozantinib as maintenance therapy for patients with “ultra-high-risk” pediatric solid tumors

Rapid Oral Abstract #10014

Pediatric Oncology II

Saturday, May 30
8:27 – 8:33 a.m. CDT

Efficacy and safety of cabozantinib (CABO) in advanced neuroendocrine tumors (NET) according to hormone functional status: Subgroup analysis of phase 3 CABINET trial (Alliance A021602)

Poster #161 Abstract #4178

Gastrointestinal Cancer – Gastroesophageal, Pancreatic and Hepatobiliary

Saturday, May 30
9:00 a.m. – 12:00 p.m. CDT

Cabozantinib in high-grade neuroendocrine neoplasms

Poster #166 Abstract #4183

Gastrointestinal Cancer – Gastroesophageal, Pancreatic and Hepatobiliary

Saturday, May 30
9:00 a.m. – 12:00 p.m. CDT

EA3231: A randomized phase 3 study of BRAF-targeted therapy vs cabozantinib in RAI-refractory differentiated thyroid cancer with BRAF V600Em

Poster #589b Abstract #TPS6140

Head and Neck Cancer

Saturday, May 30
1:30 – 4:30 p.m. CDT

Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and bone metastasis: Updated subgroup analysis of the phase 3 CheckMate-9ER trial

Poster #7 Abstract #4528

Genitourinary Cancer – Kidney and Bladder

Sunday, May 31
9:00 a.m. – 12:00 p.m. CDT

Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and liver metastasis: Subgroup analysis of the phase 3 CheckMate-9ER trial

Poster #9 Abstract

#4530

Genitourinary Cancer – Kidney and Bladder

Sunday, May 31
9:00 a.m. – 12:00 p.m. CDT

PEMBROCABOSARC: A phase 2 trial combining pembrolizumab and cabozantinib in patients with advanced undifferentiated pleomorphic sarcoma

Rapid Oral Abstract

#11514

Sarcoma

Sunday, May 31
4:42 – 4:48 p.m. CDT

MAIN-CAV: Phase 3 randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy (PBC) in patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC; Alliance A032001)

Rapid Oral Abstract #4514

Genitourinary Cancer – Kidney and Bladder

Monday, June 1
8:00 – 8:06 a.m. CDT

Final results of a phase 2 trial of cabozantinib plus nivolumab (CaboNivo) in patients with non-clear cell renal cell carcinoma (nccRCC)

Rapid Oral Abstract

#4521

Genitourinary Cancer – Kidney and Bladder

Monday, June 1
9:12 – 9:18 a.m. CDT

Survival outcomes of cabozantinib treatment with and without immune checkpoint inhibition in patients with heavily pretreated advanced sarcoma

Poster #341 Abstract #11551

Sarcoma

Monday, June 1
1:30 – 4:30 p.m. CDT

Safety and feasibility of cabozantinib (CABO) in combination with cisplatin, doxorubicin, and high-dose methotrexate (MAP) in patients with newly diagnosed high-risk osteosarcoma (OS)

Poster #281 Abstract #10030

Pediatric Oncology

Monday, June 1
1:30 – 4:30 p.m. CDT

Zanzalintinib

Contribution of atezolizumab (atezo) to the efficacy of the zanzalintinib (zanza) + atezo combination in patients (pts) with previously treated metastatic colorectal cancer (mCRC): Evidence from the phase 3 STELLAR-303 trial

Poster #341 Abstract #3574

Gastrointestinal Cancer – Colorectal and Anal

Saturday, May 30
9:00 a.m. – 12:00 p.m. CDT

ZAMBONI: A phase 2 study of zanzalintinib for metastatic clear cell renal cell carcinoma with bone metastases previously treated with immune checkpoint inhibitors

Poster #110b Abstract #TPS4634

Genitourinary Cancer – Kidney and Bladder

Sunday, May 31
9:00 a.m. – 12:00 p.m. CDT

A phase 2 trial of neoadjuvant zanzalintinib (ZANZA) plus nivolumab (NIVO) in patients with locally advanced and/or surgically challenging clear cell renal cell carcinoma (EXPLORE-RCC)

Poster #108a Abstract

#TPS4629

Genitourinary Cancer – Kidney and Bladder

Sunday, May 31
9:00 a.m. – 12:00 p.m. CDT

LITESPARK-033: Phase 3 study of belzutifan plus zanzalintinib versus cabozantinib for recurrent clear cell renal cell carcinoma during or after adjuvant anti-PD-(L)1 therapy

Poster #110a Abstract #TPS4633

Genitourinary Cancer – Kidney and Bladder

Sunday, May 31
9:00 a.m. – 12:00 p.m. CDT

About CABOMETYX® (cabozantinib)
In the U.S., CABOMETYX tablets are approved as monotherapy for the treatment of patients with advanced RCC and in combination with nivolumab as a first-line treatment for patients with advanced RCC; for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib; for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible; for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic NET; and adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET. CABOMETYX tablets have also received regulatory approvals in over 65 countries outside the U.S. and Japan, including the EU. In 2016, Exelixis granted Ipsen Pharma SAS exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan. In 2017, Exelixis granted exclusive rights to Takeda Pharmaceutical Company Limited for the commercialization and further clinical development of cabozantinib for all future indications in Japan. Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage: CABOMETYX can cause severe and fatal hemorrhages. The incidence of Grade 3-5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies. Discontinue CABOMETYX for Grade 3-4 hemorrhage and before surgery. Do not administer to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena.

Perforations and Fistulas: Fistulas, including fatal cases, and gastrointestinal (GI) perforations, including fatal cases, each occurred in 1% of CABOMETYX patients. Monitor for signs and symptoms, and discontinue CABOMETYX in patients with Grade 4 fistulas or GI perforation.

Thromboembolic Events: CABOMETYX can cause arterial or venous thromboembolic events. Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients. Fatal thrombotic events have occurred. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events.

Hypertension and Hypertensive Crisis: CABOMETYX can cause hypertension, including hypertensive crisis. Hypertension was reported in 37% (16% Grade 3 and <1% Grade 4) of CABOMETYX patients. In CABINET (n=195), hypertension occurred in 65% (26% Grade 3) of CABOMETYX patients. Do not initiate CABOMETYX in patients with uncontrolled hypertension. Monitor blood pressure regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled; when controlled, resume at a reduced dose. Permanently discontinue CABOMETYX for severe hypertension that cannot be controlled with antihypertensive therapy or for hypertensive crisis.

Cardiac Failure: CABOMETYX can cause severe and fatal cardiac failure. Cardiac failure occurred in 0.5% of patients treated with CABOMETYX as a single agent, including fatal cardiac failure in 0.1% of patients. Consider baseline and periodic evaluations of left ventricular ejection fraction. Monitor for signs and symptoms of cardiovascular events. Withhold and resume at a reduced dose upon recovery or permanently discontinue depending on the severity.

Diarrhea: CABOMETYX can cause diarrhea and it occurred in 62% (10% Grade 3) of treated patients. Monitor and manage patients using antidiarrheals as indicated. Withhold CABOMETYX until improvement to ≤ Grade 1; resume at a reduced dose.

Palmar-Plantar Erythrodysesthesia (PPE): CABOMETYX can cause PPE and it occurred in 45% of treated patients (13% Grade 3). Withhold CABOMETYX until PPE resolves or decreases to Grade 1 and resume at a reduced dose for intolerable Grade 2 PPE or Grade 3 PPE.

Hepatotoxicity: CABOMETYX in combination with nivolumab in RCC can cause hepatic toxicity with higher frequencies of Grades 3 and 4 ALT and AST elevations compared to CABOMETYX alone. With the combination of CABOMETYX and nivolumab, Grades 3 and 4 increased ALT or AST were seen in 11% of patients. Monitor liver enzymes before initiation of treatment and periodically. Consider more frequent monitoring as compared to when the drugs are administered as single agents. Consider withholding CABOMETYX and/or nivolumab, initiating corticosteroid therapy, and/or permanently discontinuing the combination for severe or life-threatening hepatotoxicity.

Adrenal Insufficiency: CABOMETYX in combination with nivolumab can cause primary or secondary adrenal insufficiency. Adrenal insufficiency occurred in 4.7% (15/320) of patients with RCC who received CABOMETYX with nivolumab, including Grade 3 (2.2%), and Grade 2 (1.9%) adverse reactions. Withhold CABOMETYX and/or nivolumab and resume CABOMETYX at a reduced dose depending on severity.

Proteinuria: Proteinuria was observed in 8% of CABOMETYX patients. Monitor urine protein regularly during CABOMETYX treatment. For Grade 2 or 3 proteinuria, withhold CABOMETYX until improvement to ≤ Grade 1 proteinuria; resume CABOMETYX at a reduced dose. Discontinue CABOMETYX in patients who develop nephrotic syndrome.

Osteonecrosis of the Jaw (ONJ): CABOMETYX can cause ONJ and it occurred in <1% of treated patients. Perform an oral examination prior to CABOMETYX initiation and periodically during treatment. Advise patients regarding good oral hygiene practices. Withhold CABOMETYX for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures. Withhold CABOMETYX for development of ONJ until complete resolution; resume at a reduced dose.

Impaired Wound Healing: CABOMETYX can cause impaired wound healing. Withhold CABOMETYX for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of CABOMETYX after resolution of wound healing complications has not been established.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS): CABOMETYX can cause RPLS. Perform evaluation for RPLS and diagnose by characteristic finding on MRI any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS.

Thyroid Dysfunction: CABOMETYX can cause thyroid dysfunction, primarily hypothyroidism, and it occurred in 19% of treated patients (0.4% Grade 3). Assess for signs of thyroid dysfunction prior to the initiation of CABOMETYX and monitor for signs and symptoms during treatment.

Hypocalcemia: CABOMETYX can cause hypocalcemia, with the highest incidence in DTC patients. Based on the safety population, hypocalcemia occurred in 13% of CABOMETYX patients (2% Grade 3 and 1% Grade 4).

Monitor blood calcium levels and replace calcium as necessary during treatment. Withhold and resume CABOMETYX at a reduced dose upon recovery or permanently discontinue CABOMETYX depending on severity.

Embryo-Fetal Toxicity: CABOMETYX can cause fetal harm. Advise pregnant women of the potential risk to a fetus and advise females of reproductive potential to use effective contraception during treatment with CABOMETYX and for 4 months after the last dose.

ADVERSE REACTIONS

The most common (≥20%) adverse reactions are:

CABOMETYX as a single agent: diarrhea, fatigue, PPE, decreased appetite, hypertension, nausea, vomiting, weight decreased, and constipation.

CABOMETYX in combination with nivolumab: diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: If coadministration with strong CYP3A4 inhibitors cannot be avoided, reduce the CABOMETYX dosage. Avoid grapefruit or grapefruit juice.

Strong or Moderate CYP3A4 Inducers: If coadministration with strong or moderate CYP3A4 inducers cannot be avoided, increase the CABOMETYX dosage. Avoid St. John’s wort.

USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed during CABOMETYX treatment and for 4 months after the final dose.

Hepatic Impairment: In patients with moderate hepatic impairment, reduce the CABOMETYX dosage. Avoid CABOMETYX in patients with severe hepatic impairment.

Pediatric Use: Physeal widening has been observed in children with open growth plates when treated with CABOMETYX. Physeal and longitudinal growth monitoring is recommended in children (12 years and older) with open growth plates. Consider interrupting or discontinuing CABOMETYX if abnormalities occur. The safety and effectiveness of CABOMETYX in pediatric patients less than 12 years of age have not been established.

Please see accompanying full Prescribing Information https://www.cabometyx.com/downloads/CABOMETYXUSPI.pdf.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

About Zanzalintinib
Zanzalintinib is a novel oral kinase inhibitor that inhibits the activity of the TAM kinases (TYRO3, AXL, MER), MET and VEGF receptors. These kinases play important roles in oncogenic processes, including tumor cell proliferation, metastasis, angiogenesis, drug resistance and evasion of antitumor immunity. The zanzalintinib development program includes a series of ongoing and planned pivotal trials to explore its therapeutic potential in CRC, clear cell and non-clear cell RCC, and NET, as well as earlier-stage trials in meningioma, lung cancer and castration-resistant prostate cancer.

In February 2026, Exelixis announced that the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application for zanzalintinib, in combination with atezolizumab (Tecentriq®), for the treatment of adult patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS wild-type, an anti-epidermal growth factor receptor (EGFR) therapy. The FDA assigned a Prescription Drug User Fee Act target action date of December 3, 2026.

Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials.

About Exelixis
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our pipeline of franchise molecules, including our novel oral kinase inhibitor zanzalintinib, and to extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements related to: Exelixis’ planned presentations for cabozantinib and zanzalintinib, including new analyses from the phase 3 CABINET and STELLAR-303 trials, at the 2026 ASCO Annual Meeting; Exelixis’ strategy to build upon the well-established therapeutic profile of CABOMETYX and accelerate the development of zanzalintinib, its next oncology franchise molecule; Exelixis’ dedication to improving the standards of care for patients with cancer; and Exelixis’ scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis’ continuing compliance with applicable legal and regulatory requirements; the potential failure of cabozantinib or zanzalintinib to demonstrate safety and/or efficacy in clinical trials; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib or zanzalintinib; the costs of conducting clinical trials; Exelixis’ dependence on third-party vendors for the development, manufacture and supply of cabozantinib and zanzalintinib; Exelixis’ ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis’ marketed products; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption “Risk Factors” in Exelixis’ most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis’ future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis.

TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group.

More News From Exelixis, Inc.
2026-06-12 13:11 2mo ago
2026-05-23 05:04 3mo ago
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near
EXEL Exelixis
FMP Stock News
Original source text
Exelixis Reports Solid Earnings—Are New Highs Back on the Table?Exelixis NASDAQ: EXEL remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president of strategy, said during a session hosted by RBC Capital Markets.

Peters said Exelixis’ guidance reflects continued growth for CABO, driven by the company’s existing business and the launch in neuroendocrine tumors, or NETs. He said the company is focused on gaining market share in renal cell carcinoma, or RCC, while also building momentum in NETs.

Get Exelixis alerts:

3 Stocks to Buy for a Soft Landing, If There Is One“It’s really kind of that singular focus on making sure that we’re going out every day and talking about CABO, talking about the data, and that again, driving market share,” Peters said.

CABO Growth Centers on RCC and NETs In RCC, Peters acknowledged that oncology remains highly competitive, including emerging activity around HIF-2 targeting therapies. He said Exelixis is closely watching recent and ongoing data in the space, including LITESPARK studies and the company’s own clinical efforts.

3 Strong Biotech Performers To Watch As Sector Nears BreakoutPeters said CABO remains the “number one IO/TKI” and “number one IO” in its market, and the company wants to preserve that position. He also noted investor discussion around whether adoption of lenvatinib in second-line RCC could support greater CABO use in the first-line setting, saying that would be an outcome Exelixis would be “okay with,” given duration dynamics.

On NETs, Peters said Exelixis has seen enthusiasm for CABO, particularly following the CABINET data. He said adoption began in the academic setting, but the company is also emphasizing community physicians, where many patients are treated. A recent sales force expansion is intended to support both the NET launch and lay groundwork for a potential zanzalintinib launch.

Peters said NETs are a relatively indolent disease, making refill dynamics important as patients remain on therapy. He said Exelixis’ guidance incorporates growth in both RCC and NETs.

Zanzalintinib Development Includes NET and Colorectal Cancer Discussing zanzalintinib in NETs, Peters said the company sees differences between CABO and zanzalintinib, including what he described as a potentially more user-friendly profile, shorter half-life and potentially better tolerability based on earlier observations.

He contrasted CABINET, which evaluated a later-line population and was placebo-controlled, with the 3-11 study, which is intended to answer what should be the first oral option for certain NET patients. Peters said the study is in an earlier population and compares zanzalintinib head-to-head against everolimus, the current standard of care.

In colorectal cancer, Peters said the nearest-term zanzalintinib opportunity is tied to STELLAR-303. He said the study’s intent-to-treat population, which read out last year, includes patients with and without liver metastases and has a PDUFA date in December. Exelixis is also awaiting a data update in the non-liver metastasis population.

Peters said the ideal outcome would be a data set that allows the company’s commercial organization to communicate why zanzalintinib plus atezolizumab should become a standard of care for later-line colorectal cancer patients. He highlighted the potential importance of an immunotherapy-containing, chemotherapy-free regimen in a population that may have already received chemotherapy throughout much of its treatment journey.

Exelixis Preparing for Potential CRC Launch Peters said Exelixis’ regulatory interactions have gone well so far, describing the process with the FDA as collegial and collaborative. He said the company has experience working with the agency and that the filing and review have proceeded as well as Exelixis could hope.

If approved, Peters said Exelixis intends to compete broadly across colorectal cancer treatment settings, targeting both academic and community prescribers. He said the company’s sales force expansion completed last quarter was designed not only to accelerate the NET launch but also to prepare for a potential zanzalintinib approval later this year.

Peters reiterated that Exelixis views the colorectal cancer opportunity as a potential $1.5 billion market when applying contemporary pricing and duration assumptions. He described the current later-line market as fragmented, with roughly one-third of patients treated with the SUNLIGHT regimen, one-third with TKIs and one-third with various chemotherapy-type options.

“Our goal, our mission, our singular focus, again, is to make sure that we’re taking as much share from each of those three buckets as we can,” Peters said.

RCC Strategy Looks Toward the 2030s Exelixis is also awaiting data this year from STELLAR-304 in non-clear cell RCC. Peters said the area has limited data and no formally approved treatment options specific to the setting. He said current treatment decisions are often driven by inference from clear cell RCC and guideline recommendations based on sparse data sets.

Peters said Exelixis believes STELLAR-304 can provide robust evidence to help define treatment for non-clear cell RCC patients. He described non-clear cell RCC as a meaningful opportunity because it represents about 20% of a large market.

More broadly, Peters said Exelixis sees zanzalintinib as central to its next phase in RCC. He said CABO has been the TKI in RCC for the 2020s, while Exelixis wants zanzalintinib to be the TKI in RCC for the 2030s. The company is studying zanzalintinib across non-clear cell, post-adjuvant, frontline and later-line RCC settings.

Peters also discussed collaborations involving HIF inhibitors, including work with Merck. He said Exelixis believes combinations such as zanzalintinib with belzutifan could help answer important treatment questions, including what patients should receive if cancer returns after adjuvant pembrolizumab.

MRD-Positive Colorectal Cancer Study Adds New Approach Peters also highlighted the 316 study, an adjuvant trial in minimal residual disease-positive colorectal cancer patients. The study involves Natera’s Signatera test and evaluates zanzalintinib alone or in combination with Merck’s Keytruda.

He said ctDNA testing can identify patients at high risk of relapse, but the current standard is largely to watch and wait. Peters said Exelixis hopes the study can determine whether zanzalintinib, with or without Keytruda, can extend disease-free survival for these patients.

He said Exelixis is working with Natera to operationalize the study and believes the ability to identify eligible patients could support clinical trial execution.

About Exelixis NASDAQ: EXELExelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Exelixis Right Now?Before you consider Exelixis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.

While Exelixis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
2026-06-12 13:11 2mo ago
2026-05-23 17:26 3mo ago
Exelixis: Financial Performance Improves Faster Than Market Expectations
EXEL Exelixis
FMP Stock News
Original source text
Exelixis remains undervalued despite a 13%+ rally post-Q1, supported by robust double-digit growth, sector-leading profitability, and strong free cash flow. Q1 revenue grew 10% year-over-year, driven almost entirely by CABOMETYX demand; operating margin expanded to 41.1% as costs fell. I maintain a Buy rating with a $57 target, reflecting 13% upside; DCF and peer multiples confirm the valuation gap persists.
2026-06-12 13:11 2mo ago
2026-05-27 10:00 3mo ago
Caring Men Global Partners with Exelixis to Launch “Strong Caregivers, Stronger Survivors” Caregiver Training Initiative
EXEL Exelixis
FMP Stock News
Original source text
CHEVY CHASE, Md.--(BUSINESS WIRE)-- #Biotech--Caring Men Global, a nonprofit dedicated to supporting male caregivers facing a loved one's cancer, has received a grant from Exelixis to launch “Strong Caregivers, Stronger Survivors,” a caregiver-centered cancer recurrence prevention program designed to prepare men to effectively support cancer survivors following treatment. Survivors are often most vulnerable after active treatment ends, when medical oversight decreases and responsibility for prevention, mo.
2026-06-12 13:11 2mo ago
2026-05-27 16:05 3mo ago
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
EXEL Exelixis
FMP Stock News
Original source text
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in June: 2026 Jefferies Global Healthcare Conference: Exelixis is scheduled to present at 11:05 a.m. ET / 8:05 a.m. PT on Wednesday, June 3 in New York City. Goldman Sachs 47th Annual Global Healthcare Conference: Exelixis is scheduled to present at 10:40 a.m. ET / 7:40 a.m. PT on Tuesday, June 9 in Miami. To access the.
2026-06-12 13:11 2mo ago
2026-05-28 03:00 3mo ago
Exelixis, Inc. (EXEL) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
EXEL Exelixis
FMP Stock News
Original source text
Exelixis, Inc. (EXEL) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
2026-06-12 13:11 2mo ago
2026-05-28 10:23 3mo ago
If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket
EXEL Exelixis
FMP Stock News
Original source text
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Ridofranz / iStock via Getty Images

When Wall Street’s growth-at-any-price trade cools, capital tends to rotate toward profitable, cash-generative healthcare names, a pattern that has played out across decades of monetary cycles. With the S&P 500 trading at rich multiples and earnings expectations leaning heavily on tech, investors hunting for under-the-radar names near $50 a share have a reason to look at oncology specialists with real cash flow rather than speculative pipeline-only biotechs.

With that in mind, here is one biotech stock trading near $50 that fits the profile of a defensive growth name analysts believe still has room to run.

Exelixis (NASDAQ: EXEL) Exelixis (NASDAQ:EXEL | EXEL Price Prediction) is an oncology-focused biotechnology company headquartered in Alameda, California, that discovers and commercializes targeted cancer therapies, most notably CABOMETYX in kidney, liver, and thyroid cancers.

Shares trade near $50, after a 12.05% gain over the past month and a 14.15% year-to-date advance. For a retail investor, that price point still buys a profitable mid-cap biotech with a $12.58 billion market capitalization rather than a speculative clinical-stage name.

Fundamentals back up the price action. Q1 2026 non-GAAP EPS came in at $0.87, beating consensus by 14.02%, on revenue of $610.81 million, up 9.97% year over year. Operating income jumped 34.51% and net income climbed 31.86%. That marks four consecutive earnings beats with surprise margins between 14.02% and 17.17%.

The stock trades at a trailing P/E of 17 and a forward P/E of 16, with an analyst target price of $49.65 reflecting one strong buy, nine buy, and nine hold ratings. H.C. Wainwright carries a $54 price target with a Buy rating.

The bull case is straightforward. CABOMETYX is the number one prescribed TKI in renal cell carcinoma, and global cabozantinib franchise revenue grew 12.5% year over year to $764 million in Q1. Management is sitting on roughly $1.4 billion in cash and marketable securities and just authorized a new $750 million buyback running through December 31, 2027, on top of completing the prior $750 million program. Layered on top is the December 3, 2026 PDUFA date for zanzalintinib in previously treated metastatic colorectal cancer, an indication CEO Michael Morrissey called “the top priority for the entire Exelixis, Inc. organization,” with a market opportunity management pegs at approximately $1.5 billion. FY2026 guidance of $2.525 billion to $2.625 billion in total revenue explicitly excludes any zanzalintinib launch contribution, leaving room for upside.

The key risk is concentration. The cabozantinib franchise still generates the overwhelming majority of revenue, and a regulatory delay or rejection of zanzalintinib would remove the most-watched near-term catalyst. Clinical disappointments, such as the LightSpark-012 readout management referenced, are a reminder that “triplet therapy in clear cell renal cell carcinoma is not an easy game.” Generic pressure on cabozantinib later this decade also looms.

With a beta of 0.385, profitable operations, an aggressive buyback, and a binary catalyst landing in December, EXEL looks like the kind of cash-generative oncology name that historically benefits when defensive healthcare comes back into favor.

A share price near $50 is a frame of reference, not a thesis. Concentration risk, FDA outcomes, and broader sector rotation can all move quickly, so readers should treat this as a starting point for their own due diligence rather than a recommendation, and size any position around their own risk tolerance and time horizon.
2026-06-12 13:11 2mo ago
2026-05-30 10:00 3mo ago
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
EXEL Exelixis
FMP Stock News
Original source text
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held fr.
2026-06-12 13:11 2mo ago
2026-06-01 10:51 3mo ago
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
EXEL Exelixis
FMP Stock News
Original source text
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Exelixis (EXEL - Free Report) Alameda, CA-based Exelixis, Inc. is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company is leveraging its investments, expertise and strategic partnerships to target an expanding range of tumor types and indications with its clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics.

EXEL is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Momentum investors should take note of this Medical stock. EXEL has a Momentum Style Score of A, and shares are up 15.6% over the past four weeks.

Five analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.14 to $3.55 per share. EXEL boasts an average earnings surprise of +17%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, EXEL should be on investors' short list.
2026-06-12 13:11 2mo ago
2026-06-03 10:40 3mo ago
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
EXEL Exelixis
FMP Stock News
Original source text
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Exelixis (EXEL - Free Report) Alameda, CA-based Exelixis, Inc. is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company is leveraging its investments, expertise and strategic partnerships to target an expanding range of tumor types and indications with its clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics.

EXEL is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 13.69; value investors should take notice.

For fiscal 2026, five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.14 to $3.55 per share. EXEL boasts an average earnings surprise of +17%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, EXEL should be on investors' short list.
2026-06-12 13:11 2mo ago
2026-06-03 16:02 3mo ago
Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
EXEL Exelixis
FMP Stock News
Original source text
Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
2026-06-12 13:11 2mo ago
2026-06-04 10:46 3mo ago
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
EXEL Exelixis
FMP Stock News
Original source text
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Exelixis (EXEL - Free Report) Alameda, CA-based Exelixis, Inc. is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company is leveraging its investments, expertise and strategic partnerships to target an expanding range of tumor types and indications with its clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics.

EXEL is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. EXEL has a Growth Style Score of A, forecasting year-over-year earnings growth of 14.6% for the current fiscal year.

For fiscal 2026, five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.16 to $3.53 per share. EXEL boasts an average earnings surprise of +17%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, EXEL should be on investors' short list.
2026-06-12 13:11 2mo ago
2026-06-04 12:36 3mo ago
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?
EXEL Exelixis
FMP Stock News
Original source text
It has been about a month since the last earnings report for Exelixis (EXEL - Free Report) . Shares have added about 6% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Exelixis due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Exelixis, Inc. before we dive into how investors and analysts have reacted as of late.

EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus

Exelixis reported mixed results for the first quarter of 2026.

Adjusted earnings per share (EPS) of 87 cents comfortably beat the Zacks Consensus Estimate of 75 cents. The company posted adjusted EPS of 62 cents in the year-ago quarter. Adjusted earnings exclude the impact of stock-based compensation expenses.

Including stock-based compensation expense, EPS was 79 cents compared with 55 cents in the year-ago period.

The bottom-line growth benefited from lower operating expenses and a decrease in shares outstanding due to ongoing buybacks.

Net revenues of $611 million missed the Zacks Consensus Estimate of $613 million. The top line was up 10% year over year.

EXEL’s Q1 Results in Detail

Net product revenues of $555.0 million were up from $513.3 million in the year-ago quarter. Management attributed the increase to higher sales volume.

Cabometyx (cabozantinib) generated revenues of $552.8 million, which missed the Zacks Consensus Estimate of $558 million and our model estimate of $564 million. The drug is approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma.

In March 2025, Exelixis obtained FDA approval for the label expansion of Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors (pNET).

The drug was also approved for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET).  

Cometriq (cabozantinib capsules) generated $2.2 million in net product revenues for treating medullary thyroid cancer.  

Collaboration revenues, comprising license and collaboration services revenues, totaled $55.8 million, up 32.4% year over year. The improvement reflected higher royalty revenues from ex-U.S. cabozantinib sales generated by Ipsen and higher milestone-related revenues recognized during the period.

Research and development expenses amounted to $199.9 million, down from $212.2 million in the prior-year quarter due to lower clinical trial and manufacturing costs.

Selling, general and administrative expenses totaled $139.6 million, up 1.8% year over year, primarily due to increases in marketing activities, legal and advisory fees, and personnel expenses.

As of the end of the first quarter of 2026, Exelixis repurchased $590.6 million of its shares under the $750 million share repurchase program (SRP) authorized in October 2025. The company expects to complete the remaining portion of this program in May 2026, ahead of its original commitment to finish by Dec. 31, 2026.

Since initiating its first SRP in March 2023, Exelixis has repurchased a total of $2.59 billion of its common stock, retiring 86.8 million shares at an average price of $29.86 per share as of quarter-end.

In May 2026, the company’s board of directors approved a new $750 million SRP, with authorization extending through Dec. 31, 2027. This marks the sixth SRP launched since March 2023.

EXEL Reaffirms 2026 Guidance

Exelixis has reiterated its guidance for 2026. The company expects total revenues of $2.525-$2.625 billion in 2026. Net product revenues are projected to be in the range of $2.325-$2.425 billion.

Exelixis’ 2026 net product revenue guidance includes a 3.0% increase in wholesale acquisition costs for Cabometyx and Cometriq in the United States, effective Jan. 1, 2026.

The annual guidance excludes any contribution from a potential approval of zanzalintinib in metastatic colorectal cancer (CRC).

Operating expenses are projected to increase. The company expects R&D expenses of $875-$925 million and SG&A expenses of $575-$625 million.

Key Pipeline and Regulatory Updates From EXEL

The company is developing zanzalintinib, a next-generation oral investigational tyrosine kinase inhibitor (TKI).

In February 2026, the FDA accepted EXEL’s new drug application seeking approval of zanzalintinib in previously treated metastatic CRC — in combination  with Tecentriq (atezolizumab). The regulatory body assigned a target action date of Dec. 3, 2026.

The NDA is supported by positive phase III STELLAR-303 data demonstrating a statistically significant reduction in the risk of death compared with Stivarga (regorafenib).

Roche’s Tecentriq is a cancer immunotherapy that is approved around the world, either alone or in combination with targeted therapies and/or chemotherapies, for various types of cancer.

Exelixis is gearing up for the potential first commercial launch of zanzalintinib for the above-mentioned indication.  

A phase III study, STELLAR-304, is evaluating zanzalintinib in combination with Opdivo (nivolumab) versus Sutent (sunitinib) in previously untreated patients with advanced non-clear cell RCC. Top-line results are expected in the second half of 2026, based on current event rates.

Earlier this year, Exelixis collaborated with Natera for the STELLAR-316 study. This phase III study is being sponsored by Exelixis. The study will evaluate zanzalintinib, with and without an immune checkpoint inhibitor, in patients with resected stage II/III CRC.

Patients with CRC who are molecular residual disease (MRD)-positive based on Natera’s Signatera test following completion of definitive therapy — and who have no radiographic evidence of disease — will be eligible for enrollment in the STELLAR-316 trial. Exelixis expects to initiate this study in mid-2026.

Exelixis also collaborated with pharma giant Merck in October 2024 to advance zanzalintinib.

In April 2026, Merck initiated LITESPARK-034, a phase II trial evaluating zanzalintinib plus Welireg (belzutifan) versus Welireg and placebo in previously treated advanced RCC patients who progressed after PD-1/L1 and VEGFR-TKI therapies.

This marks the second Merck-sponsored phase III study under the collaboration, following LITESPARK-033 (launched in December 2025), which is assessing the combination against cabozantinib in first-line advanced RCC post-adjuvant immunotherapy.

Exelixis also announced two additional studies of zanzalintinib — STELLAR-202, a planned phase II trial evaluating the drug in combination with MRK’s blockbuster drug Keytruda (pembrolizumab) as maintenance therapy in squamous non-small cell lung cancer, and a new expansion cohort in the ongoing phase Ib/II STELLAR-002 study assessing zanzalintinib plus docetaxel in metastatic castration-resistant prostate cancer patients with measurable disease. Exelixis plans to launch STELLAR-202 and open the STELLAR-002 expansion cohort in the second half of 2026.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates review.

VGM ScoresCurrently, Exelixis has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Charting a somewhat similar path, the stock was allocated a score of B on the value side, putting it in the top 40% for value investors.

Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Exelixis has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerExelixis belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Agios Pharmaceuticals (AGIO - Free Report) , has gained 2.6% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026.

Agios Pharmaceuticals reported revenues of $20.75 million in the last reported quarter, representing a year-over-year change of +137.7%. EPS of -$1.69 for the same period compares with -$1.55 a year ago.

For the current quarter, Agios Pharmaceuticals is expected to post a loss of $1.74 per share, indicating a change of +9.8% from the year-ago quarter. The Zacks Consensus Estimate has changed -4.6% over the last 30 days.

Agios Pharmaceuticals has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.
2026-06-12 13:11 2mo ago
2026-06-09 14:42 3mo ago
Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
EXEL Exelixis
FMP Stock News
Original source text
Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-06-12 13:11 2mo ago
2026-06-10 08:25 3mo ago
Exelixis Hits High on Growing Sales, Institutional Inflows
EXEL Exelixis
FMP Stock News
Original source text
Drug adoption and a strong pipeline see institutions send Exelixis, Inc. (EXEL) shares to all-time highs.

EXEL is an oncology company that discovers, develops, and commercializes new treatments for hard-to-treat cancers. Its first-quarter 2026 report showed $611 million in quarterly revenue, GAAP net income of $210.5 million ($0.79 per diluted share), $1.4 billion in cash, along with $430.8 million in repurchases last quarter and another $750 million authorized for more.

It’s no wonder EXEL shares are up 21% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are once again betting heavily on the forward picture of the stock.

Institutional Inflows Finding Exelixis Institutional volumes reveal plenty. In the last year, EXEL has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in EXEL shares. They reflect our proprietary inflow signal, pushing the stock higher:

Source: www.moneyflows.com Plenty of healthcare names are under accumulation right now. But there’s a powerful fundamental story happening with Exelixis.

Exelixis Fundamental Analysis Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, EXEL has had strong sales and earnings growth:

3-year sales growth rate (+13%) 3-year EPS growth rate (+83.6%) Source: FactSet

Also, EPS is estimated to ramp higher this year by +12.4%.

Now it makes sense why the stock has been generating Big Money interest. EXEL has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

Exelixis has been a top-rated stock at MoneyFlows. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Outlier 20 report 29 times, rising 125% since the first outlier inflow signal. The blue bars below show when EXEL was a top pick since 2017…Big Money keeps buying:

Source: www.moneyflows.com Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Exelixis Price Prediction The EXEL action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in EXEL at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights.

Related Articles

Gold Price Forecast: Correction Appears Near CompletionOld Dominion’s Increased Demand Drives Big InflowsAI, Institutional Buying Sends Micron Shares Up by 758%About the Author

Lucas is a well-versed equity investor and educator. He currently is co-founder of research and analytics firm, MAPsignals.com, which focuses on finding outlier stocks by following the Big Money.

Editors’ Picks
2026-06-12 13:11 2mo ago
2026-03-23 08:00 5mo ago
COMSTOCK RESOURCES, INC. ANNOUNCES SELECTION OF WESTERN HAYNESVILLE SITE TO HOST POWER GENERATION HUB
CRK Comstock Resources
FMP Stock News
Original source text
FRISCO, TX, March 23, 2026 (GLOBE NEWSWIRE) -- Comstock Resources, Inc. ("Comstock" or the "Company") (NYSE: CRK) announced today that the Western Haynesville will host the recently announced Texas Natural Gas-Fired Power Generation Hub in Anderson County Texas.

The selection was announced on March 20, 2026, by the United States Department of Commerce in connection with Japan's $550 billion investment commitment to the United States as part of the U.S.- Japan trade deal. The selected project is the result of the collaboration of the Company and NextEra Energy, Inc. ("NextEra") (NYSE: NEE) to develop a power generation project near Comstock’s Western Hayneville natural gas operations.

The Texas Power Generation Hub will be owned jointly by Japan and the U.S. under the structure of the joint trade agreement and will be built and operated by NextEra, the largest energy infrastructure builder in the United States. The investment is subject to negotiation and execution of definitive documents by NextEra and various constituents, as well as NextEra's completion of development, construction and commissioning of the selected project.

The Anderson County Texas facility will have up to 5.2 GW of natural gas-fired generation capable of serving up to 5 GW of large-load demand. Comstock will provide natural gas supply for the facility which could reach almost 1 Bcf per day by 2031. The estimated cost of the facility is $16 billion.

Located within the rapidly growing ERCOT market, the project takes advantage of Comstock’s abundant natural gas supply and strong transmission infrastructure at Bethel, Texas to deliver dispatchable power at scale to serve large‑scale users, including data centers and advanced manufacturing.

The projects would be structured so that new electricity demand is met with new generating resources, intended to avoid upward pressure on electricity bills for consumers.

About Comstock Resources

Comstock is a leading independent natural gas producer with operations focused on the development of the Haynesville shale in North Louisiana and East Texas. The Company's stock is traded on the New York Stock Exchange under the symbol CRK.

This press release may contain "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described herein. Although the Company believes the expectations in such statements to be reasonable, there can be no assurance that such expectations will prove to be correct.
2026-06-12 13:11 2mo ago
2026-03-24 17:58 5mo ago
Comstock Resources: Increasing The Bet On The Western Haynesville
CRK Comstock Resources
FMP Stock News
Original source text
Comstock Resources, Inc. secures a natural gas supply agreement with NextEra Energy for data center power. Cost reduction efforts in Western Haynesville are ongoing. Low production and transportation costs support CRK's high margins relative to peers.
2026-06-12 13:11 2mo ago
2026-03-30 11:26 5mo ago
Europe's LNG Refill Race: Tailwind for U.S. Natural Gas?
CRK Comstock Resources
FMP Stock News
Original source text
Key Takeaways Europe's gas storage sits well below normal, forcing early refill demand for LNG imports.Global LNG supply is tightening due to disruptions in Qatar. Australia and key shipping routes.Cheniere Energy and Comstock Resources are positioned to benefit from strong LNG export demand. Europe is entering a crucial phase for natural gas. Winter is over, but storage levels across the region remain much lower than normal. Governments are already urging utilities and energy companies to refill inventories early so they are not caught short before next winter. At the same time, disruptions in Qatar, Australia and the Strait of Hormuz have tightened global LNG supply. That combination is creating a stronger backdrop for U.S. natural gas producers and exporters. Even though Henry Hub prices remain near $3 per MMBtu, the global market is showing signs that demand for U.S. LNG could stay firm through the rest of 2026.

At this stage, investors may want to stay focused on natural gas names with strong exposure to production growth and LNG exports, including EQT Corporation (EQT - Free Report) , Cheniere Energy (LNG - Free Report) and Comstock Resources (CRK - Free Report) .

Europe Needs to Refill QuicklyEurope entered spring with gas storage levels well below normal. EU inventories were only around 28% full near the end of March, while the Netherlands was down to just 6%. Policymakers have already warned that waiting too long to refill storage could lead to a rush for supply later in the year.

That matters because Europe still depends heavily on imported LNG. If storage buying begins early and continues through the summer, it could create steady demand for U.S. cargoes. European gas prices are already far above U.S. levels, with the Dutch benchmark trading close to six times Henry Hub prices. The price gap gives U.S. LNG exporters a strong incentive to keep volumes flowing overseas.

Global Supply Problems Are Not Going AwayThe supply picture has become more difficult after damage to Qatar’s LNG facilities and shipping disruptions in the Strait of Hormuz. Qatar is one of the world’s largest LNG suppliers, and any outage there has an immediate effect on Europe and Asia.

Australian LNG problems are adding to the pressure. Chevron said its Wheatstone LNG plant could take weeks to return to full output, while Woodside’s Karratha facility is still facing cyclone-related disruptions. Analysts have already cut their 2026 LNG supply forecasts, with some expecting up to 35 million tons of supply to disappear from the market.

Why U.S. Natural Gas Stocks Could BenefitU.S. export terminals are already running near full capacity. Strong overseas demand continues to support domestic producers and exporters. Companies with significant LNG export infrastructure and direct exposure to global gas markets stand to benefit the most. Producers may also gain if sustained export demand gradually lifts domestic gas prices. Even if mild U.S. weather caps near-term price upside, tighter global balances could create a more favorable backdrop for natural gas stocks than in recent months.

Europe’s refill season is just getting underway, and several uncertainties remain. Weather patterns, storage levels and geopolitical developments will be key to watch. Still, the overall setup appears more supportive than it did earlier this year.

3 Stocks to MonitorFor natural gas-focused investors, this may be a good time to watch companies that can benefit from stronger LNG exports and firmer gas demand. EQT Corporation, Cheniere Energy and Comstock Resources remain three names worth focusing on as the global gas market continues to tighten.

EQT: It is the premier natural gas producer in the domestic market based on average daily sales volumes. With primary emphasis on the Appalachian Basin, spanning Ohio, Pennsylvania and West Virginia, the company’s share of natural gas in its overall production/sales is more than 90%.

EQT beat the Zacks Consensus Estimate for earnings in each of the last four quarters. The natural gas producer, with a Zacks Rank #3 (Hold), has a trailing four-quarter earnings surprise of roughly 13%, on average. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Cheniere Energy: It is a leading U.S. LNG producer and exporter, operating large-scale facilities along the Gulf Coast. Since starting exports in 2016, it has grown into the largest LNG producer in the United States, supplying customers across more than 40 global markets with reliable and cleaner-burning energy.

Backed by firm gas supply agreements for its Sabine Pass and Corpus Christi facilities, this Zacks Rank #3 company enjoys strong cash flow visibility and solid long-term growth prospects. The Zacks Consensus Estimate for Cheniere Energy’s 2026 earnings per share indicates 26.1% year-over-year growth.

Comstock Resources: It is an independent natural gas producer based in Frisco, TX, with operations concentrated in north Louisiana and East Texas. Comstock Resources — currently a #3 Ranked stock — is fully focused on developing the Haynesville and Bossier shales, two of the largest gas plays in the United States.

CRK holds a large acreage position across Haynesville, giving it direct exposure to Gulf Coast LNG demand growth. Its production is 100% natural gas, making it one of the most gas-levered E&Ps in the sector. The Zacks Consensus Estimate for Comstock Resources’ 2026 earnings per share indicates 35.2% year-over-year surge. The firm has a trailing four-quarter earnings surprise of roughly 56.9%, on average.
2026-06-12 13:11 2mo ago
2026-04-05 02:50 5mo ago
Comstock Resources, Inc. (NYSE:CRK) Given Average Recommendation of “Reduce” by Analysts
CRK Comstock Resources
FMP Stock News
Original source text
Posted by Defense World Staff on Apr 5th, 2026

Comstock Resources, Inc. (NYSE:CRK – Get Free Report) has been assigned a consensus rating of “Reduce” from the ten ratings firms that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and one has given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $20.8750.

A number of research firms recently weighed in on CRK. Bank of America lowered shares of Comstock Resources from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $27.00 to $24.00 in a research report on Friday, January 16th. Morgan Stanley set a $19.00 target price on shares of Comstock Resources in a research note on Friday, February 13th. UBS Group set a $17.00 target price on Comstock Resources in a report on Friday, February 13th. Citigroup upped their price target on Comstock Resources from $23.00 to $24.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Finally, Mizuho lifted their price objective on Comstock Resources from $21.00 to $29.00 and gave the stock a “neutral” rating in a research report on Friday, December 12th.

Check Out Our Latest Report on Comstock Resources

Comstock Resources Stock Down 0.2% NYSE CRK opened at $19.50 on Friday. The business has a fifty day moving average price of $20.76 and a 200 day moving average price of $21.44. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.49 and a current ratio of 0.49. The company has a market cap of $5.73 billion, a P/E ratio of 13.83 and a beta of 0.39. Comstock Resources has a one year low of $14.65 and a one year high of $31.17.

Comstock Resources (NYSE:CRK – Get Free Report) last announced its earnings results on Wednesday, February 11th. The oil and gas producer reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.05. The company had revenue of $787.32 million for the quarter, compared to analysts’ expectations of $504.66 million. Comstock Resources had a net margin of 17.80% and a return on equity of 6.30%. The firm’s quarterly revenue was up 115.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.16 EPS. Research analysts anticipate that Comstock Resources will post 0.54 EPS for the current fiscal year.

Insider Transactions at Comstock Resources In other Comstock Resources news, VP Patrick Mcgough sold 48,915 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $21.20, for a total value of $1,036,998.00. Following the completion of the sale, the vice president directly owned 187,516 shares of the company’s stock, valued at $3,975,339.20. This trade represents a 20.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows Several institutional investors and hedge funds have recently modified their holdings of CRK. CreativeOne Wealth LLC increased its position in Comstock Resources by 3.7% during the third quarter. CreativeOne Wealth LLC now owns 13,931 shares of the oil and gas producer’s stock worth $276,000 after purchasing an additional 500 shares during the last quarter. Natixis Advisors LLC boosted its holdings in Comstock Resources by 2.0% in the 4th quarter. Natixis Advisors LLC now owns 29,703 shares of the oil and gas producer’s stock valued at $689,000 after purchasing an additional 572 shares during the last quarter. Carrera Capital Advisors boosted its holdings in Comstock Resources by 0.7% in the 4th quarter. Carrera Capital Advisors now owns 82,910 shares of the oil and gas producer’s stock valued at $1,922,000 after purchasing an additional 606 shares during the last quarter. Uhlmann Price Securities LLC boosted its holdings in Comstock Resources by 2.4% in the 3rd quarter. Uhlmann Price Securities LLC now owns 27,653 shares of the oil and gas producer’s stock valued at $548,000 after purchasing an additional 650 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Comstock Resources by 12.1% in the 4th quarter. GAMMA Investing LLC now owns 6,303 shares of the oil and gas producer’s stock valued at $146,000 after buying an additional 679 shares during the period. Institutional investors and hedge funds own 36.13% of the company’s stock.

About Comstock Resources (Get Free Report)

Comstock Resources, Inc is an independent energy company engaged in the acquisition, exploration, development and production of oil and natural gas properties in the United States. The company focuses on generating long-term value through the efficient development of unconventional resource plays and conventional prospects. Its activities encompass drilling, completion and production operations, as well as the marketing of natural gas, natural gas liquids and crude oil.

Comstock holds a core position in the Haynesville Shale of Northwest Louisiana, one of the most active natural gas plays in North America, and has built a complementary portfolio in the Delaware Basin of West Texas.

Read More Five stocks we like better than Comstock Resources

Receive News & Ratings for Comstock Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comstock Resources and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINESummer Energy (OTCMKTS:SUME) versus AES (NYSE:AES) Critical Comparison

NEXT HEADLINE »Vertex, Inc. (NASDAQ:VERX) Given Average Rating of “Hold” by Analysts
2026-06-12 13:11 2mo ago
2026-04-05 04:43 5mo ago
Comstock Resources, Inc. $CRK Shares Purchased by JPMorgan Chase & Co.
CRK Comstock Resources
FMP Stock News
Original source text
Posted by Defense World Staff on Apr 5th, 2026

JPMorgan Chase & Co. grew its stake in shares of Comstock Resources, Inc. (NYSE:CRK – Free Report) by 31.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 177,326 shares of the oil and gas producer’s stock after acquiring an additional 42,416 shares during the quarter. JPMorgan Chase & Co. owned about 0.06% of Comstock Resources worth $3,516,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Capital Square LLC grew its holdings in Comstock Resources by 34.1% in the third quarter. Capital Square LLC now owns 20,580 shares of the oil and gas producer’s stock valued at $408,000 after purchasing an additional 5,229 shares during the period. CIBC Bancorp USA Inc. purchased a new position in Comstock Resources during the third quarter worth approximately $205,000. Advisory Services Network LLC acquired a new position in shares of Comstock Resources in the 3rd quarter valued at $27,000. Caxton Associates LLP acquired a new position in shares of Comstock Resources in the 3rd quarter valued at $5,051,000. Finally, Woodline Partners LP grew its stake in shares of Comstock Resources by 50.5% during the 3rd quarter. Woodline Partners LP now owns 1,231,916 shares of the oil and gas producer’s stock valued at $24,429,000 after buying an additional 413,611 shares during the period. 36.13% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth CRK has been the topic of several research reports. UBS Group set a $17.00 target price on Comstock Resources in a research report on Friday, February 13th. Mizuho boosted their price target on Comstock Resources from $21.00 to $29.00 and gave the company a “neutral” rating in a research report on Friday, December 12th. Citigroup upped their price target on Comstock Resources from $23.00 to $24.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Bank of America lowered Comstock Resources from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $27.00 to $24.00 in a research note on Friday, January 16th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Comstock Resources in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $20.88.

Check Out Our Latest Research Report on CRK

Comstock Resources Stock Performance NYSE:CRK opened at $19.50 on Friday. The firm’s fifty day simple moving average is $20.76 and its 200 day simple moving average is $21.44. The company has a current ratio of 0.49, a quick ratio of 0.49 and a debt-to-equity ratio of 0.95. Comstock Resources, Inc. has a twelve month low of $14.65 and a twelve month high of $31.17. The firm has a market capitalization of $5.73 billion, a price-to-earnings ratio of 13.83 and a beta of 0.39.

Comstock Resources (NYSE:CRK – Get Free Report) last released its quarterly earnings data on Wednesday, February 11th. The oil and gas producer reported $0.16 EPS for the quarter, beating the consensus estimate of $0.11 by $0.05. The company had revenue of $787.32 million for the quarter, compared to analyst estimates of $504.66 million. Comstock Resources had a return on equity of 6.30% and a net margin of 17.80%.The firm’s revenue was up 115.5% compared to the same quarter last year. During the same period last year, the company posted $0.16 earnings per share. As a group, equities research analysts expect that Comstock Resources, Inc. will post 0.54 earnings per share for the current fiscal year.

Insiders Place Their Bets In other Comstock Resources news, VP Patrick Mcgough sold 48,915 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $21.20, for a total value of $1,036,998.00. Following the completion of the sale, the vice president owned 187,516 shares of the company’s stock, valued at $3,975,339.20. This trade represents a 20.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.20% of the stock is currently owned by corporate insiders.

Comstock Resources Profile (Free Report)

Comstock Resources, Inc is an independent energy company engaged in the acquisition, exploration, development and production of oil and natural gas properties in the United States. The company focuses on generating long-term value through the efficient development of unconventional resource plays and conventional prospects. Its activities encompass drilling, completion and production operations, as well as the marketing of natural gas, natural gas liquids and crude oil.

Comstock holds a core position in the Haynesville Shale of Northwest Louisiana, one of the most active natural gas plays in North America, and has built a complementary portfolio in the Delaware Basin of West Texas.

Featured Articles Five stocks we like better than Comstock Resources

Receive News & Ratings for Comstock Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comstock Resources and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEJPMorgan Chase & Co. Boosts Stake in Navigator Holdings Ltd. $NVGS

NEXT HEADLINE »JPMorgan Chase & Co. Sells 11,675 Shares of iShares Core 5-10 Year USD Bond ETF $IMTB
2026-06-12 13:11 2mo ago
2026-04-08 09:00 5mo ago
COMSTOCK RESOURCES, INC. ANNOUNCES FIRST QUARTER 2026 EARNINGS DATE AND CONFERENCE CALL INFORMATION
CRK Comstock Resources
FMP Stock News
Original source text
FRISCO, TX, April 08, 2026 (GLOBE NEWSWIRE) -- Comstock Resources, Inc. (NYSE:CRK) plans to release its first quarter 2026 results on May 5, 2026 after the market closes and host its quarterly conference call at 10:00 a.m. CT on May 6, 2026 to discuss the first quarter results.  

Parties interested in participating in the conference call telephonically will need to register at https://register-conf.media-server.com/register/BIfdab657d67b245688283195b41fda6fb. Upon registering to participate in the conference call, participants will receive the dial-in number and a personal PIN number to access the conference call. On the day of the call, please dial in at least 15 minutes in advance to ensure a timely connection to the call.

~~~

The conference call will also be broadcast live in listen-only mode and can be accessed via the website URL: https://edge.media-server.com/mmc/p/p77w7mi4.

~~~

A replay of the first quarter 2026 conference call will be available for twelve months beginning at 1:00 p.m. CT on May 6, 2026. The replay of the conference can be accessed using the webcast link: https://edge.media-server.com/mmc/p/p77w7mi4.

About Comstock Resources:

Comstock Resources is a leading independent natural gas producer with operations focused on the development of the Haynesville Shale in North Louisiana and East Texas.

A slide show presentation on the financial results will be available on Comstock's website at www.comstockresources.com. Click on “Quarterly Results” to view the slide show.
2026-06-12 13:11 2mo ago
2026-04-14 13:11 4mo ago
Will Comstock (CRK) Beat Estimates Again in Its Next Earnings Report?
CRK Comstock Resources
FMP Stock News
Original source text
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Comstock Resources (CRK - Free Report) , which belongs to the Zacks Oil and Gas - Exploration and Production - United States industry.

This oil and gas company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 85.23%.

For the most recent quarter, Comstock was expected to post earnings of $0.11 per share, but it reported $0.16 per share instead, representing a surprise of 45.45%. For the previous quarter, the consensus estimate was $0.04 per share, while it actually produced $0.09 per share, a surprise of 125.00%.

Price and EPS Surprise

For Comstock, estimates have been trending higher, thanks in part to this earnings surprise history. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Comstock has an Earnings ESP of +13.33% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #3 (Hold), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on May 5, 2026.

Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.

Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.

Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
2026-06-12 13:11 2mo ago
2026-04-25 02:30 4mo ago
Comstock Resources (NYSE:CRK) and HKN (OTCMKTS:HKNI) Head to Head Survey
CRK Comstock Resources
FMP Stock News
Original source text
Posted by Defense World Staff on Apr 25th, 2026

Comstock Resources (NYSE:CRK – Get Free Report) and HKN (OTCMKTS:HKNI – Get Free Report) are both energy companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Earnings & Valuation This table compares Comstock Resources and HKN”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Comstock Resources $2.22 billion 2.24 $395.61 million $1.41 12.02 HKN N/A N/A N/A N/A N/A Comstock Resources has higher revenue and earnings than HKN.

Profitability This table compares Comstock Resources and HKN’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Comstock Resources 17.80% 6.30% 2.39% HKN N/A N/A N/A Insider & Institutional Ownership 36.1% of Comstock Resources shares are held by institutional investors. 2.2% of Comstock Resources shares are held by insiders. Comparatively, 0.1% of HKN shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations This is a summary of recent ratings and target prices for Comstock Resources and HKN, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Comstock Resources 3 6 1 0 1.80 HKN 0 0 0 0 0.00 Comstock Resources presently has a consensus target price of $20.88, suggesting a potential upside of 23.18%. Given Comstock Resources’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Comstock Resources is more favorable than HKN.

Summary Comstock Resources beats HKN on 9 of the 9 factors compared between the two stocks.

About Comstock Resources (Get Free Report)

Comstock Resources, Inc., an independent energy company, engages in the acquisition, exploration, development, and production of natural gas and oil properties in the United States. Its assets are located in the Haynesville and Bossier shales located in North Louisiana and East Texas. The company was incorporated in 1919 and is headquartered in Frisco, Texas. Comstock Resources, Inc. is a subsidiary of Arkoma Drilling, L.P.

About HKN (Get Free Report)

HKN, Inc. operates as an independent energy company. The company owns an oilfield emulsion breaking technology that purifies oilfield emulsions by breaking and separating the emulsions into oil, water, and solids. It also holds non-operated oil and gas leases and mineral interests in properties located in the Bakken and Niobrara shale oil plays; and rights to acreage in the Permian Basin of Texas. The company was founded in 1973 and is based in Southlake, Texas.

Receive News & Ratings for Comstock Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comstock Resources and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEGlobal Payments Inc. (NYSE:GPN) Receives Average Recommendation of “Hold” from Analysts

NEXT HEADLINE »Meridian Holdings Inc. Common Stock (NASDAQ:MRDN) & CCC Intelligent Solutions Holdings Inc. Common Stock (NASDAQ:CCC) Financial Comparison
2026-06-12 13:11 2mo ago
2026-05-05 21:31 4mo ago
Comstock Resources (CRK) Q1 Earnings Lag Estimates
CRK Comstock Resources
FMP Stock News
Original source text
Comstock Resources (CRK - Free Report) came out with quarterly earnings of $0.15 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this oil and gas company would post earnings of $0.11 per share when it actually produced earnings of $0.16, delivering a surprise of +45.45%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Comstock, which belongs to the Zacks Oil and Gas - Exploration and Production - United States industry, posted revenues of $587.35 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 16.26%. This compares to year-ago revenues of $512.85 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Comstock shares have lost about 23.3% since the beginning of the year versus the S&P 500's gain of 5.2%.

What's Next for Comstock?While Comstock has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Comstock was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.07 on $433.34 million in revenues for the coming quarter and $0.67 on $2.04 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Oil and Gas - Exploration and Production - United States is currently in the top 5% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

W&T Offshore (WTI - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 7.

This independent oil and gas company is expected to post quarterly loss of $0.02 per share in its upcoming report, which represents a year-over-year change of +84.6%. The consensus EPS estimate for the quarter has been revised 41% higher over the last 30 days to the current level.

W&T Offshore's revenues are expected to be $136.98 million, up 5.5% from the year-ago quarter.
2026-06-12 13:11 2mo ago
2026-05-06 20:31 4mo ago
Comstock Resources, Inc. (CRK) Q1 2026 Earnings Call Transcript
CRK Comstock Resources
FMP Stock News
Original source text
Comstock Resources, Inc. (CRK) Q1 2026 Earnings Call Transcript
2026-06-12 13:11 2mo ago
2026-06-04 12:36 3mo ago
Why Is Comstock (CRK) Down 11.7% Since Last Earnings Report?
CRK Comstock Resources
FMP Stock News
Original source text
It has been about a month since the last earnings report for Comstock Resources (CRK - Free Report) . Shares have lost about 11.7% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Comstock due for a breakout? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Comstock Resources, Inc. before we dive into how investors and analysts have reacted as of late.

Comstock Q1 Earnings Miss Estimates on Lower ProductionComstock Resources reported first-quarter 2026 adjusted earnings of 15 cents per share, which missed the Zacks Consensus Estimate of 23 cents by 34.8%. The bottom line declined from the year-ago level of 18 cents. 

Total quarterly revenues of $587.3 million topped the Zacks Consensus Estimate of $505.2 million by 16.3%. The top line increased 14.5% from the prior-year figure of $512.8 million.

The weak quarterly earnings can be attributed to lower production volume due to severe weather conditions. Higher average natural gas price realizations and improved gas services revenues partially offset the negatives.

CRK’s Production Fell, but New Wells Supported a ReboundTotal production averaged 97,919 million cubic feet equivalent (MMcfe), lower than the year-ago quarter’s level of 115,091 MMcfe. This represented a drop of roughly 14.9%, aligning with management’s statement that weather dampened volumes in the quarter. Natural gas production declined to 97,855 million cubic feet (MMcf) from 115,029 MMcf a year ago.

The company’s operational execution remained active. During the quarter, 17 operated Haynesville/Bossier wells were drilled and 13 brought into sales, setting up volume recovery for the remainder of 2026.

CRK’s Price Realization IncreasedAverage natural gas price realization (before hedging) came in at $4.27 per thousand cubic feet (Mcf), up from $3.58 per Mcf in the prior-year quarter. Total price realization (before hedging) averaged $4.28 per thousand cubic feet equivalent (Mcfe) compared with $3.59 per Mcfe in the first quarter of 2025.

Comstock’s Revenue Mix Benefits From Gas ServicesWhile earnings missed estimates, revenue strength was broad-based. Natural gas sales were $418.3 million, modestly ahead of the prior year’s figure of $412.3 million, reflecting better pricing despite lower volumes. Oil sales were $0.8 million, slightly higher than $0.7 million recorded in the year-ago quarter.

Gas services revenues were standout contributors, having increased to $166.5 million from $99.9 million in the year-ago quarter. Management attributed the increase primarily to higher natural gas prices tied to sales of gas purchased to utilize excess transport capacity. The gas services segment generated a positive margin of $3.6 million against a loss of $16.9 million a year earlier.

CRK’s Unit Costs Rose as Expenses ShiftedCRK’s production cost averaged 93 cents per Mcfe, up from 83 cents per Mcfe a year ago. The cost structure per Mcfe for the first quarter of 2026 included 43 cents for gathering and transportation costs, 29 cents for lease operating expenses, 10 cents for production and ad valorem taxes, and 11 cents for cash general and administrative expenses compared with 37 cents, 30 cents, 10 cents and 6 cents, respectively, in the year-ago quarter.

Margins remained healthy but reflected the impact of hedging and cost mix. The company reported an unhedged operating margin of 78% in the quarter and a hedged operating margin of 73% compared with 77% and 76%, respectively, in the previous year. On the expense lines, general and administrative costs increased year over year due to higher employee compensation and stock-based compensation, while depreciation, depletion and amortization declined in line with the lower production base.

Total operating expenses in the quarter came in at $412.5 million, higher than the $386.7 million reported a year ago. Gas services expenses rose to $162.9 million from $116.8 million in the fourth quarter of 2025.

Comstock’s Hedging Results Drive a Wide Profit BridgeHedging was a major swing factor in reported profitability. Comstock recorded realized hedging losses of $80.4 million in the quarter, while recognizing a pre-tax unrealized gain of $82.8 million tied to changes in future natural gas prices since the fourth quarter of 2025.

GAAP net income was $112.5 million, or 38 cents per diluted share, even though the company’s adjusted performance was more subdued. A year ago, the same was at a loss of $115 4 million, or 40 cents loss per share. Adjusted net income declined to $44.5 million from the year-ago figure of $53.8 million, while adjusted EBITDAX totaled $251.3 million compared with $293 million in the prior-year quarter.

CRK’s Cash Generation Stays Solid Despite Heavy SpendOperating cash flow (excluding working capital changes) was $191.9 million, or 66 cents per share, highlighting the earnings power of the Haynesville position even in a weather-impacted quarter.

CRK exited the quarter with $14.8 million of cash and cash equivalents, and reported total debt of $3 billion. Liquidity was $1.3 billion, reflecting borrowing capacity under its revolving credit facilities and cash on hand. Capital spending remained elevated, with total capital expenditures of $417.1 million in the quarter, including $343.3 million of exploration and development capital expenditures.

Comstock’s Strategic Power Hub Adds a Longer-Term AngleBeyond the quarter’s financials, Comstock highlighted a power generation opportunity tied to its Western Haynesville footprint. The company noted that the region was selected to host a natural gas-fired power generation hub in Anderson County, TX. The facility is aimed at delivering dispatchable power at scale, and having up to 5.2 GW of gas-fired generation.

The $16-billion project will be constructed and operated by NextEra, the country’s biggest builder of energy infrastructure. It will be jointly owned by the United States and Japan, per the agreement. Comstock expects to supply natural gas to the facility, with potential demand nearing 1 Bcf per day by 2031, offering a tangible pathway to support future regional gas demand alongside its drilling-driven production recovery narrative.

How Have Estimates Been Moving Since Then?It turns out, estimates review have trended downward during the past month.

The consensus estimate has shifted -17.86% due to these changes.

VGM ScoresAt this time, Comstock has a average Growth Score of C, a score with the same score on the momentum front. Charting a somewhat similar path, the stock has a score of B on the value side, putting it in the second quintile for value investors.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Comstock has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
2026-06-12 13:11 2mo ago
2026-06-10 20:41 2mo ago
Comstock Resources Inc (CRK) Stock Up 5.5% and Still Undervalued -- GF Score: 65/100
CRK Comstock Resources
FMP Stock News
Original source text
On June 10, 2026, Comstock Resources Inc CRK shares rose 5.5% today, closing at $13.37. The stock has seen significant fluctuations over the past year, trading in a 52-week range of $12.44 to $31.17.

GF Value™ verdict: Current price of $13.37 is 21.9% below GF Value™ of $17.11, indicating the stock is undervalued.GF Score™: 65/100, suggesting the stock is rated above average in terms of overall quality.Most notable signal: No insider transactions have occurred in the last 3 months. Is CRK Overvalued or Undervalued? The current price of Comstock Resources Inc CRK at $13.37 is significantly below the GF Value™ estimate of $17.11, indicating a 21.9% margin of safety for potential investors. This undervaluation suggests an opportunity, though it is crucial to consider the overall market conditions and the company's financial health. The GF Valuation label categorizes CRK as modestly undervalued, which implies that while there is potential for appreciation, investors should remain cautious due to the inherent risks associated with the oil and gas industry.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. The presence of a modest undervaluation could attract interest, but investors should also be aware of the company’s volatility and external market factors that could influence future performance.

How Does CRK's Valuation Compare to Its History? MetricCurrentHistorical P/E (TTM)6.2x6.7x Forward P/E20.7xN/A The current P/E (TTM) of 6.2x is 8% below its 5-year median P/E of 6.7x. This indicates that CRK is trading below its historical valuation, which aligns with the GF Value™ verdict of being undervalued. The forward P/E of 20.7x suggests that there may be expectations for increased earnings; however, this figure must be interpreted cautiously given the current market conditions and the company's recent performance.

What Does CRK's GF Score™ Tell Us? MetricRating GF Score™65 Financial Strength4/10 Profitability6/10 Growth6/10 Valuation8/10 Momentum1/10 The GF Score™ of 65/100 indicates that Comstock Resources Inc is positioned above average when compared to its peers. The strongest aspect of CRK's score is its valuation rank of 8/10, reflecting its current status as modestly undervalued. However, it faces challenges in financial strength with a low rating of 4/10, and a concerning momentum rank of 1/10 suggests that the stock may be experiencing weak performance trends. This combination of scores highlights the need for cautious analysis regarding CRK's potential for recovery and growth.

What Are Insiders Doing with CRK Stock? In the last 3 months, there have been no reported insider transactions involving Comstock Resources Inc CRK . The lack of insider activity can suggest that management is either confident in the company's prospects or may be waiting for more favorable conditions before making any moves. For potential investors, this could indicate a degree of caution from insiders regarding the current market environment.

What This Means for Investors Based on the GF Value™ assessment, Comstock Resources Inc CRK is currently undervalued. While the stock presents a potential investment opportunity, it is essential to consider the broader market conditions and the company's financial metrics before making any decisions.

For the complete analysis, visit the Comstock Resources Inc CRK stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is CRK's GF Score™?

The GF Score™ for Comstock Resources Inc is 65/100, indicating that it ranks above average in terms of overall quality compared to its peers.

Is CRK overvalued or undervalued?

CRK is currently undervalued, with a GF Value™ of $17.11 compared to its price of $13.37, presenting a 21.9% margin of safety.

What is CRK's P/E ratio?

CRK's P/E ratio (TTM) is 6.2x, which is 8% below its 5-year median P/E of 6.7x, indicating that the stock is trading below its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
2026-06-12 13:11 2mo ago
2026-03-23 10:41 5mo ago
Is Tidewater (TDW) Stock Outpacing Its Oils-Energy Peers This Year?
TDW Tidewater
FMP Stock News
Original source text
For those looking to find strong Oils-Energy stocks, it is prudent to search for companies in the group that are outperforming their peers. Tidewater (TDW - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Oils-Energy peers, we might be able to answer that question.

Tidewater is one of 234 individual stocks in the Oils-Energy sector. Collectively, these companies sit at #12 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Tidewater is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for TDW's full-year earnings has moved 18.8% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the most recent data, TDW has returned 43.5% so far this year. Meanwhile, stocks in the Oils-Energy group have gained about 28.8% on average. This shows that Tidewater is outperforming its peers so far this year.

Another Oils-Energy stock, which has outperformed the sector so far this year, is Ultrapar Participacoes S.A. (UGP - Free Report) . The stock has returned 30.2% year-to-date.

Over the past three months, Ultrapar Participacoes S.A.'s consensus EPS estimate for the current year has increased 5.3%. The stock currently has a Zacks Rank #2 (Buy).

To break things down more, Tidewater belongs to the Oil and Gas - Integrated - United States industry, a group that includes 12 individual companies and currently sits at #211 in the Zacks Industry Rank. Stocks in this group have gained about 35.3% so far this year, so TDW is performing better this group in terms of year-to-date returns.

On the other hand, Ultrapar Participacoes S.A. belongs to the Oil and Gas - Production and Pipelines industry. This 10-stock industry is currently ranked #91. The industry has moved +15.5% year to date.

Investors with an interest in Oils-Energy stocks should continue to track Tidewater and Ultrapar Participacoes S.A.. These stocks will be looking to continue their solid performance.
2026-06-12 13:11 2mo ago
2026-04-01 09:26 5mo ago
Axiom Announces Manola Divestiture and Additional Tidewater Midstream and Infrastructure Ltd. Lawsuit
TDW Tidewater
FMP Stock News
Original source text
Calgary, Alberta--(Newsfile Corp. - April 1, 2026) - Axiom Oil and Gas Inc. ("Axiom" or the "Company") has listed its Manola oil and gas property for sale with Sayer Energy Advisors and has filed a new claim against Tidewater Midstream and Infrastructure Ltd. ("Tidewater") for $1,136,441 plus damages for the seizure and sales of the Company's Manola gas volumes for Tidewater's own account. Axiom cannot assure a potential purchaser of the Manola property that it will be able to access sales gas pipelines and receive any payment for the produced gas wells or solution gas. This new claim is separate, and in addition to Axiom's main claim for $110 million for the Brazeau River action, where Tidewater stranded 6.3 Billion cubic feet natural gas and nearly 1 Million barrels of natural gas liquids reserves despite Axiom paying $4.5 million in advance for a Tidewater sour service plant turnaround that was not performed as scheduled in Apr. 2024, and having a Gas Handling Agreement for "P1" highest priority service for "life of reserves" and no limitation of liability. Axiom has brought the Manola and Brazeau matters to the attention of the Alberta Energy Regulator, and regulatory engagement is ongoing.

Historically, Axiom utilized a Tidewater gas gathering system that transports its Manola sales gas to a Tidewater meter station just north of Edmonton where Tidewater took possession of Axiom's Manola gas. Tidewater has been selling the gas for its own account since October 2024 without reimbursing Axiom upon request. Manola is located approximately 200 km from Brazeau and not is not in any way connected to the Manola operations. Because the Company is not receiving the gas revenue and to preserve its gas wells reserves value, Axiom recently shut in its Manola gas wells and gas plant, while it continues to produce its oil wells.

The Sayer process has bids due Apr. 2, 2026. The link may be found at the following location, and click on Manola

https://www.sayeradvisors.com/view/169/axiom-oil-and-gas-inc.

ABOUT AXIOM OIL AND GAS INC.

Axiom Oil and Gas Inc. is a growth focused Canadian energy company dedicated to generating positive shareholder returns by the responsible development of crude oil and natural gas in the Western Canadian Sedimentary Basin. Combined with an acquisition strategy targeting highly accretive, low decline, complementary opportunities, Axiom has assembled an attractive portfolio of free-cash flowing, low-decline operated assets in Central Alberta.

READER ADVISORY

Forward-Looking Information and Statements

Certain information included in this press release constitutes forward-looking information under applicable securities legislation. Forward-looking information typically contains statements with words such as "anticipate", "believe", "expect", "plan", "intend", "estimate", "propose", "project", "scheduled", "will" or similar words suggesting future outcomes or statements regarding an outlook. Forward-looking information in this press release may include, but is not limited to, the Company's drilling and development plans, cycle times, expectations regarding netbacks, the business plan, cost model and strategy of the Company.

Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date of this update. The Company does not undertake or accept any obligation or undertaking to update or revise any forward-looking statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

All dollar figures included herein are presented in Canadian dollars, unless otherwise noted.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290859

Source: Axiom Oil and Gas Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us